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Abstract 
 
Protein-Protein Interactions in the Mammalian Heme Degradation Pathway: Heme 
Oxygenase-2, Cytochrome P450 Reductase and Biliverdin Reductase  
by 
Andrea L. M. Spencer 
 
Chair: Stephen W. Ragsdale 
 
 Heme oxygenase (HO) catalyzes the rate-limiting step in the degradation of 
heme to biliverdin, CO and Fe, and requires electrons delivered from NADPH via 
cytochrome P450 reductase (CPR). Biliverdin reductase (BVR) then catalyzes 
conversion of biliverdin to bilirubin. The HO pathway is important for many cellular 
processes, including the maintenance of heme levels below toxic concentrations, iron 
homeostasis, carbon monoxide production, and antioxidant protection. Understanding 
protein-protein interactions of the heme degradation pathway will provide insight into 
potential regulatory mechanisms for the pathway. While the more well-studied HO 
isoform, HO-1, is reported to form complexes with CPR and BVR, little is known 
regarding the ability of HO-2 to bind either protein. 
 In this thesis I describe various in vitro studies aimed at evaluating interactions of 
soluble HO-2 with CPR and BVR. The 1H-15N TROSY NMR spectrum of HO-2 reveals 
specific residues, including L201, near the heme face of HO-2 that are affected by the 
addition of CPR, implicating this residue at the HO/CPR interface. Alanine substitutions 
at HO-2 residues L201 and K169 cause a respective 3- and 22-fold increase in Km for 
CPR, consistent with a role for these residues in CPR binding. Sedimentation velocity 
experiments confirm the transient nature of the HO-2/CPR complex (Kd = 15.1 µM). Our 
results also indicate that HO-2 and BVR form a very weak complex that is only 
observed by cross-linking. Fluorescence quenching experiments suggest that the 
 xiv 
previously reported high affinity of BVR for HO is artifactual, resulting from the effects of 
free heme (dissociated from HO) on BVR fluorescence.  
 Studies were also performed to evaluate the role of cysteine residues in catalytic 
activity and substrate inhibition for human BVR. Alanine substitution of C74 reduced 
catalytic activity by ~80% and this variant is less sensitive to substrate inhibition. 
Alanine substitution of C281, C292, C293 or C292/C293 had little effect on either 
catalytic activity or substrate inhibition. 
 The studies described herein elucidate mechanisms which may be important 
features of regulation for the HO system in the cell, and thus have implications for 
regulating the cellular processes affected by HO and BVR. 
 
 1 
Chapter 1 General introduction to the heme degradation system 
 
1.1 Heme biology and iron homeostasis 
 Heme is required as a prosthetic group for many biologically important processes 
including oxygen transport, electron transport, oxidation reactions, and transcriptional 
regulation. As such, it is crucial for aerobic life. A familiar role of the heme cofactor is to 
bind gases, such as for the oxygen transport and storage proteins hemoglobin and 
myoglobin (1,2). Furthermore, heme is required for electron transport in various 
proteins, e.g, cytochrome c in the respiratory chain of the mitochondria (3). Heme is 
required as a cofactor in oxygenases, such as monooxygenases like cytochrome P450, 
which insert oxygen atoms from O2 to metabolize xenobiotic compounds (4). Finally, 
heme is an important regulator of transcription factors and signaling pathways (5).   
 The basic structure of heme consists of protoporphyrin IX with ferrous iron 
inserted into the tetrapyrrole macrocycle (Figure 1.1). There are several forms of the 
heme cofactor, which differ at the methyl and vinyl side chains of the tetrapyrrole. B-
type heme, in which the molecule is noncovalently bound to the protein, is the most 
common form of the cofactor, while many cytochromes contain c-type heme in which 
thioester bonds covalently link the heme vinyl side chains to the protein. Less common 
forms of heme, such as a-type heme, found in cytochrome c oxidase, and d1-type 
heme, which is found in nitrite reductase, also exist (6).  
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Figure 1.1. Ball and stick representation of b-type heme. Heme consists of four 
pyrrole rings linked by methylene bridges (α, β, γ, δ). Oxygens on the propionate groups 
are shown in red and can interact with the protein environment via electrostatic 
interactions. Nitrogens of the pyrrole rings (blue) coordinate ferric (3+) or ferrous (2+) 
iron, shown in orange. 
 
 Heme biosynthesis in mammals is initiated in the mitochondria. The first and 
rate-limiting step of heme synthesis is the synthesis of aminolevininate acid (ALA) which 
occurs in the mitochondria and is mediated by ALA synthase. This step is negatively 
regulated by both heme and glucose (7). ALA is then transferred to the cytosol where 
the next four steps of heme synthesis occur to produce coproporphyrinogen III (COPRO 
III), which is transported back into the mitochondria where the last three steps of heme 
synthesis occur. In the final step, ferrochelatase inserts iron into protoporphyrin IX, 
forming heme. Heme is then transported out of the mitochondria via an unknown 
transporter and is incorporated into hemoproteins in the cytosol. Unincorporated heme 
is either transported out of the cell, degraded by heme oxygenases, or may act as a 
regulator of biological events (8). 
 Iron and heme homeostasis are closely linked, as in humans approximately 70% 
of the iron in the body exists as heme iron and the majority of the dialy iron requirement 
is fulfilled by the recycling of heme iron from erythrocytes (9). Iron is crucial for most 
prokaryotic and eukaryotic life, as a constituent of heme and hemoproteins (as 
described above), for iron-sulfur (Fe-S) containing proteins such as ferredoxins and 
carbon monoxide dehydrogenase (CODH), and other iron containing enzymes 
Propionate
groups
Methyl
group
Vinyl
group
α
β
γ
δ
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important for DNA synthesis, replication and repair such as ribonucleotide reductase 
(9). While iron deficiency can lead to cell death, free iron is also toxic due to its ability to 
generate reactive hydroxyl radicals via Fenton chemistry.  
 
1.2 Heme degradation and its importance in biology 
As described above, hemoproteins mediate crucial cellular and organismal 
functions such as oxygen transport, electron transport, and are required for numerous 
catalytic functions. Therefore, it is important that sufficient heme is available to be 
incorporated into hemoproteins. However, high heme levels (concentrations above 1 
µM) are cytotoxic due to the ability of heme to generate hydroxyl radicals via Fenton 
chemistry and to intercalate into cellular membranes (10). Thus, heme levels must be 
tightly regulated to provide sufficient heme for cellular processes while avoiding toxicity. 
Two major points of regulation exist for heme levels in the cell. ALA synthase is 
the major site of regulation for heme synthesis, while heme oxygenase (HO), NADPH-
cytochrome P450 reductase (CPR) and biliverdin reductase (BVR) regulate heme 
degradation.  
The HO pathway is the major enzymatic process through which cellular heme is 
degraded in the cell (Figure 1.2). HO converts heme to biliverdin (BV), requiring 7 
electrons from CPR, and 3O2 [Equation 1]. Subsequently, BVR converts biliverdin (BV) 
to bilirubin (BR) utilizing 2 electrons from NADPH [Equation 2] (11,12).  
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Figure 1.2. The heme degradation pathway. The two enzymatic steps of heme 
degradation mediated by HO, CPR and BVR. HO converts heme to biliverdin and BVR 
converts biliverdin to bilirubin.  The HO reaction requires electrons transferred from 
NADPH via CPR. (PDB 1AMO, 2QPP, and 2H63) 
 
 Heme + 7e- + 3O2 → biliverdin + CO + Fe(II) + 3H2O [Equation 1] 
 Biliverdin + 2e- → Bilirubin [Equation 2] 
 
In addition to maintaining heme homeostasis, the heme degradation pathway 
impacts cellular health through its products. The release and recycling of iron from 
heme is an important aspect of iron homeostasis as less than 3% of the daily 
requirement for iron is consumed in the diet (13). The heme degradation system not 
only prevents the accumulation of free heme, it also is protective against oxidative 
stress via its end product, bilirubin, which is a potent antioxidant (14). Finally, HO is the 
major physiologic source of CO, which is thought to be a signaling molecule akin to NO 
(15).  
 
1.3 Enzymes of the heme degradation pathway 
1.3.1 Heme oxygenase 
HO mediates the first and rate limiting enzymatic step of heme degradation, and 
the HO reaction is comprised of four major steps. Initially, molecular oxygen (O2) and 
electrons from NADPH-CPR are used to oxidize heme to α-meso-hydroxyheme (16). α-
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verdoheme is then formed and the hydroxylated α-meso carbon is released as CO. The 
third step requires reducing equivalents from CPR and O2 to convert α-verdoheme to 
biliverdin-iron. Finally, the biliverdin-iron complex is reduced, which results in the 
release of ferrous iron and biliverdin. In the absence of BVR, the limiting step in the HO 
reaction is the release of BV (17,18). 
There are two major HO isoforms: HO-1 and HO-2. While HO-3 has also been 
described, the transcript is not enzymatically active and its biological relevance is 
uncertain (19). HO-1 and HO-2 share high sequence homology (55% identity and 76% 
similarity) and structural similarity (20). Both isoforms contain related hydrophobic C-
terminal regions of approximately 20 amino acids that anchor the proteins to the 
microsomal membrane (21). HO-1 is a 288 amino acid protein with a molecular weight 
of approximately 32 kDa while HO-2 is slightly larger, with 316 amino acids and a 
molecular weight of 36 kDa. As shown in Figure 1.3, HO-1 and HO-2 are structurally 
similar and the crystal structures of the core catalytic regions of the two HOs overlay 
closely. 
 
 
Figure 1.3. HO-1 and HO-2 are structurally similar. An overlay of the crystal 
structures of the catalytic cores of HO-1 (residues 10-233; black) and HO-2 (residues 
29-242; red). (PDB files 1DVE and 2QPP). 
 
HO-1 (10-223)
HO-2 (29-242)
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 While structurally similar, the expression patterns and regulation of HO-1 and 
HO-2 are distinct. HO-1 is expressed in most tissues and is transcriptionally regulated, 
while HO-2 is constitutively expressed in a narrow range of tissues, primarily the brain 
and testes (4,22). 
HO-1, also known as heat shock protein 32 (HSP32), is induced by a variety of 
factors including heme (23), hypoxia (24), and oxidative stress (25). Both heme and 
hypoxia induce expression of HO-1 through transcriptional regulatory elements in the 5’-
flanking region of the HO-2 promoter; activator protein (AP-1) DNA binding sites (23). 
Signal transducer and activation of transcription (STAT) DNA binding sites at the HO-1 
promoter are also important for HO-1 induction under hypoxia (26). HO-1 induction by 
oxidative stress is mediated via nuclear factor (erythroid-derived 2)-like 2 (Nrf2), which 
is a transcription factor that regulates numerous genes involved in antioxidant protection 
(25,27).  
The regulation of constitutively expressed HO-2 is not fully understood, however 
HO-2 contains three Cys-Pro heme regulatory motifs (HRMs) while HO-1 completely 
lacks cysteines. The C-terminal HRMs of HO-2 form a disulfide bond in response to the 
redox state of the cell, and the disulfide state of the HRMs modulates the ability of HO-2 
to bind heme (28). Under oxidizing conditions the affinity of HO-2 for heme is increased 
10-fold compared to the reduced protein (Kd values of 0.033 μM and 0.348 μM 
respectively) (28,29). This represents one regulatory mechanism for HO-2 distinct from 
HO-1, however it is not clear why the two major HO isoforms exist. 
1.3.2 Cytochrome P450 reductase 
As stated earlier, the heme oxygenase reaction requires 7 electrons transferred 
from NADPH via CPR. CPR is a 78 kDa protein which is tethered to the microsomal 
membrane through an N-terminal membrane spanning region and transfers electrons to 
many hemoproteins including heme oxygenase (30), cytochromes p450 (31), 
cytochrome b5 (32), and cytochrome c (33); and also the flavoprotein squalene 
monooxygenase (34,35). CPR is highly expressed in the liver, and is also found in many 
extrahepatic tissues. Regulation of CPR occurs primarily at the transcriptional level by 
the thyroid hormone T3, which stimulates CPR expression (36,37).  
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The crystal structure of soluble rat CPR, which lacks the N-terminal membrane 
spanning region, has been determined and shows that CPR consists of four structural 
domains; the FMN-binding domain, the connecting domain, and the FAD- and NADPH-
binding domains (Figure 1.4) (38). To transfer electrons, CPR requires equimolar 
quantities of the bound cofactors FAD and FMN (31). The electron transfer path is 
typically from NADPH through FAD to FMN, then to the redox acceptor (HO, P450, etc) 
(39,40). CPR associates closely with many of its redox partners to mediate electron 
transport. 
 
 
Figure 1.4. Structural domains of CPR. The FMN-binding domain is shown in red, the 
connecting domain in pink, the FAD and NADP(H) domains are shown in yellow. 
Cofactors are: NADP+ (blue), FAD (purple), FMN (orange). PDB 1AMO 
 
The interaction of CPR with members of the cytochrome p450 family has been 
well studied and may exemplify CPR’s interaction with other electron acceptor proteins. 
Binding of CPR and p450 requires membrane association of both proteins, and complex 
formation occurs through a combination of electrostatic and hydrophobic interactions 
(41-44). The molecular surface of CPR surrounding FMN is predominately 
electronegative, while the surface of p450 surrounding the heme moiety is primarily 
electropositive (45). It is thought that charge coupling between the two proteins is a 
major factor in binding, however hydrophobic residues are also involved (41). 
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While the membrane-spanning region of CPR is required for electron transfer to 
cytochrome p450, other redox partners such as HO-1 and cytochrome c are reduced 
using soluble forms of both CPR and redox partner (46); however membrane 
association can enhance complex formation and electron transfer, for example with HO-
1 (47). 
A complex between the soluble forms of CPR and HO-1 (lacking their 
membrane-spanning regions) has been characterized by a variety of methods and 
suggests a relatively high affinity electron transfer complex is formed, with Kd values 
ranging from 0.4 ± 0.1 µM to 2.4 ± 0.6 µM (45,48). Like CPR and cytochrome P450, 
charge interactions are important for HO-1/CPR binding and an interface for CPR on 
HO-1 involving specific lysine residues has been proposed (48,49). While the HO-
1/CPR complex is relatively well described, the HO-2/CPR complex remains 
uncharacterized. 
 
1.3.3 Biliverdin reductase 
BVR is a 33 kDa protein that mediates the second step in heme degradation, the 
conversion of biliverdin to bilirubin (Figure 1.2). BVR or BVR-like genes are found in life 
forms ranging from cyanobacteria to humans, and in humans BVR is present in most 
tissues (12). For some time the importance of converting non-toxic biliverdin to 
potentially toxic bilirubin was not understood, however a role for bilirubin as a powerful 
antioxidant has been proposed (50).  
Mutagenesis studies using rat BVR suggest that cysteines may be required for 
BVR function, however there are conflicting reports regarding the specific residues that 
are required (51,52). The BVR reaction requires two electrons from NADPH (or NADH) 
[Equation 2] and BVR is unique in its duel cofactor specificity; the enzyme favors 
NADPH at high pH (8.7), however at pH ranges 6.7-6.9 BVR prefers NADH (53). 
NADPH is thought to be the physiologic cofactor, however, as at physiologic pH the Km 
for NADPH is ~100-fold lower compared with NADH (54).  
BVR is also unique in its diverse functions. In addition to catalyzing the 
conversion of biliverdin to bilirubin, BVR serves as a heme-sensitive transcriptional 
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regulator, a kinase that participates in insulin and AKT signaling pathways, and is 
thought to be important in the protection against oxidative stress (55). As a 
transcriptional regulator, BVR regulates genes involved in the oxidative stress response, 
including HO-1 (56,57). BVR contains a bZip motif that is commonly involved in 
homodimerization. The dimeric form of BVR, but not the monomeric form, is capable of 
binding DNA regulatory sequences and is likely responsible for BVR mediated 
transcriptional regulation (57). The kinase activity of BVR, including its 
autophosphorylation, facilitates its enzymatic activity and the phosphorylation of other 
proteins, enabling BVR to act as a signaling molecule in various pathways (55,58-61).  
Regulation of the BVR product bilirubin is essential because, while at low levels 
bilirubin is protective against oxidative stress, high levels of bilirubin result in 
neurotoxicity (14,62-65). Under normal conditions bilirubin is glucuronidated to enhance 
solubility and excreted from the body. However, impaired glucoronidation or excessive 
BVR activity results in the accumulation of bilirubin causing hyperbilirubinemia, a 
common neonatal condition that can cause severe brain damage (66).  
At the transcriptional level, BVR expression is upregulated by hypoxia, and 
inhibited by both biliverdin and NF-κB (67). Early studies characterizing rat BVR also 
show that the enzyme is strongly substrate inhibited, which may be an important aspect 
of regulating the production of bilirubin post transcriptionally (54). Two major 
mechanisms for substrate inhibition are the formation of a non-productive enzyme-
substrate complex, or the presence of a second, regulatory substrate-binding site. An 
inhibitory complex of BVR bound to biliverdin and NADP+ has been proposed as the 
inhibitory complex responsible for BVR substrate inhibition (68).  
1.4 Protein-protein interactions in the heme degradation pathway 
Recent experiments addressing protein-protein interactions in the heme 
degradation pathway focus on soluble HO-1 and its interactions with CPR or BVR. 
Methods such as surface plasmon resonance (48), fluorescence quenching (45), and 
acetylation protection assays (49) demonstrate that soluble HO-1 and soluble CPR 
(lacking their membrane spanning regions) form an electron transfer complex. 
Furthermore, NADP+ increases the affinity of HO-1 for CPR by ~5 fold (48).  
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The interaction between HO-1 and CPR is mediated in part through charge 
interactions. The surface of CPR is predominately negatively charged, while the surface 
of HO-1 near the d-meso edge of heme is positively charged (38,45). Two groups have 
addressed the importance of specific HO-1 residues in binding CPR by evaluating the 
effect of alanine substitutions on the Kd value for HO-1 and CPR using fluorescence 
quenching or surface plasmon resonance methods (45,48). These studies both 
demonstrate that mutations disrupting the charge distribution on the heme binding face 
of HO-1 (in which the heme biding picket and surrounding residues are visible) can also 
disrupt HO-1/CPR binding, however the HO-1 residues identified as important for CPR 
binding are not consistent between the two studies (Figure 1.5A and B). Fluorescence 
quenching studies identify CPR K18, K22, K179, R185, E19, E127, E190, and R198 as 
important for binding to CPR (45). The fluorescence quenching studies also show that 
alanine substitution of additional residues, including K149 or K153, does not increase 
the Kd value of HO-1 and CPR (45). In contrast, surface plasmon resonance 
experiments, identify K149, K153, and R185 of HO-1 as important for CPR binding (48). 
Mass spectroscopy studies further support the location of K149 and K153 at the HO-
1/CPR interface by demonstrating that both the lysine residues are protected from 
chemical modification in the presence of CPR, and therefore are likely at the interface of 
the two proteins (49).  
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Figure 1.5. HO-1 residues important for binding CPR. Alanine substitution of HO-1 
residues that increase the Kd are shown in red while residues that do not increase the 
Kd value are shown in blue. (A) Residues identified by fluorescence quenching studies 
for CPR and HO-1 (Wang et al, 2003). (B) Residues identified by SPR studies for HO-1 
and CPR (Higashimoto et al. 2005). (C) Residues identified by fluorescence quenching 
studies for HO-1 and BVR (Wang et al, 2003). (PDB 1DVE) 
 
The majority of studies addressing HO-1/CPR interactions were conducted in 
vitro using soluble forms of the proteins, as catalytic activity is retained in the truncated 
soluble enzymes and the soluble forms are more tractable than full-length proteins with 
intact membrane anchors. More recent studies using full length HO-1 and CPR 
establish that the membrane spanning regions and/or the membrane environment 
facilitates complex formation between HO-1 and CPR (69,70).  
 In addition to facilitating electron transport, CPR binding HO-1 may influence the 
oligomeric state of HO-1 (70). In mammalian cells under hypoxic conditions, HO-1 is 
rapidly cleaved from its membrane spanning region and translocated to the nucleus. If, 
however, CPR is coexpressed with HO-1, HO-1 is protected from proteolysis and is 
retained at the endoplasmic reticulum (70).  
 Studies similar to those used to characterize the HO-1/CPR complex also 
address the nature of an HO-1/BVR complex. Surface plasmon resonance studies 
demonstrate that BVR can compete for HO-1 binding to immobilized CPR (48), while 
fluorescence quenching studies demonstrate that HO-1 binds BVR with similar affinity 
as compared to CPR and identifies some HO-1 residues that may be important in 
binding BVR (Figure 1.5C) (45). However, while CPR and BVR are proposed to share 
an overlapping binding site on HO-1, acetylation protection studies with BVR do not 
identify any residues on HO-1 that are protected by BVR (49). 
A CB
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1.5 Unresolved questions 
As described above, the heme degradation pathway plays a role in numerous 
cell processes; detoxification, iron and heme homeostasis, cell signaling and protection 
against oxidative stress. Understanding the mechanisms that regulate the HO pathway 
and its various processes is crucial to our understanding of cellular health, and is the 
first step in our ability to manipulate this pathway therapeutically. 
It is not fully understood why two the major HO isoforms (HO-1 and HO-2) exist. 
Understanding the similarities and differences for these isoforms may shed light on 
distinct roles for the enzymes. While an HO-1/CPR complex has been well described for 
the soluble proteins (45,48,49,71), little is known regarding the ability of HO-2 to form a 
complex with CPR. Also, the nature of the membrane bound HO/CPR electron transfer 
complex in the cell is not known. Soluble HO-1 has also been reported to bind BVR, 
however while some evidence supports an HO-1/BVR complex, other challenges it 
(45,49) and the ability of BVR to form a complex with HO-2 has not been determined. 
Understanding the ability of HO-1 and HO-2 to form complexes with the other 
proteins in the heme degradation pathway (CPR and BVR) will provide insight into 
mechanisms that are important for the regulation of the HO pathway in the cell, and is 
therefore important for understanding the cellular regulation of iron and heme 
homeostasis, and the defense against oxidative stress.  
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Chapter 2 Protein-Protein Interactions in the Mammalian Heme Degradation 
Pathway: Heme Oxygenase-2, Cytochrome P450 Reductase and Biliverdin 
Reductase 
 
 This project was in collaboration with Dr. Erik Zuiderweg and Dr. Ireena Bagai at 
the University of Michigan, Ann Arbor and Dr. Donald Becker at the University of 
Nebraska, Lincoln. The results from this chapter have been submitted to J. Biol. Chem 
for publication: Spencer AM, Bagai I, Becker DF, Zuiderweg ERP, and Ragsdale, 
SW. “Protein-Protein Interactions in the Mammalian Heme Degradation Pathway: Heme 
Oxygenase-2, Cytochrome P450 Reductase and Biliverdin Reductase”. 
 In this chapter Dr. Bagai and Dr. Zuiderweg collected NMR TROSY spectra and 
Dr. Zuiderweg conducted an analyzed the NMR relaxation studies. Dr. Becker 
performed and analyzed the analytical the ultracentrifugation experiments. Andrea 
Spencer performed the sample preparation for all experiments, and both conducted and 
analyzed the studies utilizing mutagenesis, gel filtration, surface plasmon resonance, 
chemical cross linking, fluorescence quenching, and optical absorbance, and performed 
data analysis for the NMR binding experiments. 
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2.1 Abstract 
Heme oxygenase (HO) catalyzes the rate-limiting step in the O2-dependent 
degradation of heme to biliverdin, CO and Fe with electrons delivered from NADPH via 
cytochrome P450 reductase (CPR). Biliverdin reductase (BVR) then catalyzes 
conversion of biliverdin to bilirubin. We describe mutagenesis combined with kinetic, 
spectroscopic (fluorescence and NMR), surface plasmon resonance, cross-linking, gel 
filtration and analytical ultracentrifugation studies aimed at evaluating interactions of 
HO-2 with CPR and BVR. Based on these results, we propose a model in which HO-2 
and CPR form a dynamic ensemble of complex(es) that precede formation of the 
productive electron transfer complex. The 1H-15N TROSY NMR spectrum of HO-2 
reveals specific residues, including L201, near the heme face of HO-2 that are affected 
by the addition of CPR, implicating this residue at the HO/CPR interface. Alanine 
substitutions at HO-2 residues L201 and K169 cause a respective 3- and 22-fold 
increase in Km for CPR, consistent with a role for these residues in CPR binding. 
Sedimentation velocity experiments confirm the transient nature of the HO-2/CPR 
complex (Kd = 15.1 µM). Our results also indicate that HO-2 and BVR form a very weak 
complex that is only captured by cross-linking. For example, under conditions that CPR 
affects the 1H-15N TROSY NMR spectrum of HO-2, BVR has no effect. Fluorescence 
quenching experiments also suggest that BVR binds HO-2 weakly, if at all, and that the 
previously reported high affinity of BVR for HO is artifactual, resulting from the effects of 
free heme (dissociated from HO) on BVR fluorescence.  
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2.2 Introduction 
Precise regulation of heme metabolism is crucial for the cell. Heme is an active 
catalyst for generating reactive oxygen species by Fenton chemistry and is cytotoxic at 
elevated levels (above ~1µM) (1). Heme is also a required prosthetic group for many 
proteins involved in electron transfer, oxygen transport and redox enzymology (e.g., 
oxidases) (2). The mammalian heme degradation pathway consists of two enzymatic 
steps, which are mediated by heme oxygenase (HO) and biliverdin reductase (BVR) 
(Figure 2.1). Cytochrome P450 reductase (CPR) is required as an electron donor for 
HO catalysis. HO is the only known catalyst in the mammalian cell that degrades heme 
[Equation 1]. HO catalyzes the conversion of heme to biliverdin in a reaction that 
requires O2, NADPH, and CPR, which transfers seven electrons as shown in Equation 1 
(3,4). BVR then converts biliverdin to bilirubin [Equation 2], which undergoes 
conjugation with glucuronate and is excreted from the body. 
 
Heme + 7e- + 3O2 → biliverdin + CO + Fe(II) + 3H2O   [Equation 1] 
 
Biliverdin + 2e- → Bilirubin      [Equation 2] 
 
 
Figure 2.1. The heme degradation pathway. The two enzymatic steps of heme 
degradation mediated by heme oxygenase and biliverdin reductase. HO converts heme 
to biliverdin and BVR converts biliverdin to bilirubin. The HO reaction requires electrons 
transferred from NADPH via cytochrome P450 reductase. (PDB 1AMO, 2QPP, and 
2H63) 
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In addition to protecting the cell from the toxicity of free heme, the heme 
degradation pathway generates biologically important products. The HO reaction is the 
only cellular source of CO and, while high levels of CO are toxic (>500 ppm), at low 
levels, CO acts as a signaling molecule akin to NO (5,6) and is cytoprotective (7). The 
release and recycling of iron from heme is critical for iron homeostasis as most of the 
iron required for the synthesis of new ferroproteins and heme comes from recycled iron, 
with less than 3% of the daily iron requirement deriving from the diet (2,8). Finally, the 
HO system protects cells against oxidative stress, both by controlling free heme levels 
and by producing bilirubin, a potent antioxidant (9-11).  
The heme degradation pathway affects many areas of cellular health; heme and 
iron homeostasis, antioxidant protection, and gaseous signaling. As such, it is crucial to 
understand the mechanisms that regulate the activity of HO.  
HO exists as two major isoforms: HO-1 and HO-2. HO-3 has also been 
described, however it has low catalytic activity and its biological role and relevance are 
uncertain (12,13). HO-1 and HO-2 share a high degree of homology (55% identity and 
76% similarity) and display similar enzymatic activity (14). The two isoforms, however, 
have distinct patterns of expression and regulation. HO-1 is transcriptionally regulated 
and is expressed in most tissues, while HO-2 is constitutively expressed in a narrow 
range of tissues, primarily the brain and testes (15). Both HOs possess C-terminal 
membrane-spanning regions that tether them to the endoplasmic reticulum. However, 
due to poor solubility of the full-length protein, most enzymatic studies (as those 
described in this paper) have been conducted with a stable soluble form of HO lacking 
the C-terminal region. A major difference between the two HOs is that HO-2 contains 
three heme regulatory motifs (HRMs), consisting of a Cys-Pro dyad, while HO-1 
completely lacks cysteines (16). Two of these HRMs are at the C-terminus of HO-2, just 
preceding the membrane-spanning section. When these are in the dithiol state, the 
affinity of HO-2 for heme (relative to the disulfide state) decreases significantly, 
suggesting that the HRMs act as a redox switch that controls activity in response to 
changes in cellular redox poise (17-19). 
Electrons are transferred to HO from NADPH via the ~77-kDa dual flavin enzyme 
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CPR through a pathway that involves its bound cofactors, FAD and FMN (20-23). In the 
cell, CPR is tethered to the ER by an N-terminal membrane-spanning region. Protein-
protein interactions between the soluble forms of HO-1 and CPR and between HO-1 
and BVR have been described in vitro (24-27) and are an aspect of regulation that has 
not been addressed for HO-2. CPR also forms electron-transfer complexes with the 
cytochromes P450, cytochrome b5, cytochrome c, and squalene monoxygenase (23,28-
31). Interactions with CPR may help define distinct roles for the HO isoforms. For 
example, recent reports suggest that binding of HO-1 and CPR regulates HO-1 nuclear 
translocation and the transcriptional regulatory response under hypoxia by stabilizing 
the ER-tethered form of HO-1 in the cell (32). On the other hand, HO-2 appears to 
remain stably associated at the ER irrespective of hypoxic challenge (32).  
The complex between the soluble forms of CPR and HO-1 (lacking their 
membrane-spanning regions) has been characterized by fluorescence quenching (27), 
surface plasmon resonance (SPR) (24), and acetylation protection assays (25). These 
reports provide Kd values for the HO-1/CPR complex that range from 0.4 ± 0.1 µM to 
2.4 ± 0.6 µM. CPR protects lysine residues 149 and 153 in HO-1 from chemical 
modification, suggesting that these basic residues are at the interface of the HO-1/CPR 
complex (25). Additionally, SPR studies indicate that the K149A substitution results in 
an ~10-fold increase in Kd for the HO-1/CPR complex (24). While the HO-1/CPR 
complex has been relatively well characterized, the HO-2/CPR complex has not. 
BVR catalyzes the second step in heme degradation: the reduction of biliverdin 
to bilirubin [Eq 2]. BVR is a soluble ~33 kDa protein that utilizes two electrons from 
either NADH or NADPH making it unique in having dual cofactor specificity at distinct 
pH values (33). In addition to its canonical enzymatic function, BVR has also been 
shown to bind and traffic heme to the nucleus where it regulates HO-1 expression (34-
37). Also, BVR is a dual specificity (Ser/Thr and Tyr) kinase, and as such is implicated 
in MAPK (mitogen-activated protein kinase) cell signaling pathways (38,39).  
Two groups have reported interactions between HO-1 and BVR via fluorescence 
quenching studies and surface plasmon resonance studies (SPR) (24,27). The 
fluorescence quenching studies suggest a high affinity HO-1/BVR complex (Kd = 0.2 
µM) is formed while SPR studies report that BVR competes with CPR for binding to HO-
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1. However, studies that identified the HO-1/CPR interface via lysine acetylation 
protection assays failed to find evidence for an HO-1/BVR interaction (25). Under single 
turnover conditions, the rate-limiting step of the HO-1 reaction is the release of 
biliverdin; however, in the presence of BVR, this step is accelerated (40), which 
indicates kinetic coupling between these two enzymes. Thus, while some evidence 
supports the formation of a high-affinity complex between HO-1 and BVR, other 
challenges it. Furthermore, to our knowledge, the extent to which HO-2 is able to 
interact with BVR has not been addressed. Protein-protein interactions between HO and 
its reaction partners may play an important role in regulating its various properties, 
including cellular localization and enzymatic activity. Furthermore, given that they exhibit 
different modes of transcriptional regulation, HO-1 and constitutive HO-2 may differ in 
their affinity for BVR and CPR.  
In order to gain insight into the protein-level mode of regulating HO-2 activity, and 
to resolve some of the discrepancies related to measured interactions (or lack thereof) 
of HO-1 and HO-2 with their binding partners, we have performed nuclear magnetic 
resonance (NMR), kinetic, analytical ultracentrifugation, gel filtration, cross-linking, SPR 
and fluorescence quenching studies. Our experiments indicate that both HO-1 and HO-
2 form complexes with CPR. The interaction between HO-2 and BVR, however, is weak 
as compared to CPR, and can only be detected by irreversible methods such as cross-
linking. Our results allow us to propose an interface for the HO-2/CPR complex near the 
heme-binding face of HO-2 that includes residues L201 and K169. Furthermore, our 
studies demonstrate that the HO/CPR interface includes both hydrophobic and charge 
interactions. Our studies suggest a reinterpretation of protein-protein interactions in the 
heme degradation pathway. We demonstrate that both HO-1 and HO-2 bind CPR in a 
transient electron-transfer complex that is required for HO activity. On the other hand, 
interactions between BVR and HO-2 are weak to undetectable and may not play a 
significant role in the physiologic context of a cell. 
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2.3 Materials and methods 
2.3.1 Materials 
 Ampicillin, isopropyl-β-D-thio-galactopyranoside, kanamycin, NADPH, NADP+, 
riboflavin, and hemin were purchased from Sigma (St Louis, MO). 7-Diethylamino-3-(4’-
maleimidylphenyl)-4-methylcoumarin (CPM) was purchased from Molecular probes, Inc. 
(Eugene, OR). OneShot® BL21(DE3) chemically competent cells were purchased from 
Invitrogen/Life Technologies (Grand Island, NY). Ni-nitrilotriacetic acid (NTA) resin is 
from Qiagen (Valencia, CA). Glutathione Sepharose was purchased from GE 
Healthcare (Piscataway, NJ). 
2.3.2 Enzyme purification 
 Truncated versions of human HO-1265 containing residues 1-265, and human 
HO-2288 containing residues 1-288, and variants of these enzymes, were used in these 
studies. These enzymes lack the C-terminal amino acids that comprise their membrane 
anchors and will be referred to as HO-1 and HO-2. To facilitate expression, solubility 
and ease of purification, HO-1 was cloned into the expression vector pMCSG10 by 
ligation independent cloning (LIC) (41). HO-2 was expressed and purified from the 
pET28a(+) vector. HO-1 and HO-2 were purified via an N-terminal 6xHis tag using Ni-
NTA affinity chromatography according to the manufacturer’s guidelines (Qiagen, 
Valencia, CA). 
Human CPRΔ66 lacking the N-terminal membrane anchor was expressed from the 
pET28a(+) vector and is referred to as CPR for all studies described herein. CPR was 
expressed in BL21(DE3) cells and purified according to published methods (42). Human 
BVR was expressed from the pGEX-4T-2 vector and purified via Glutathione Sepharose 
affinity resin according to the manufacturer’s instructions (GE Healthcare, Piscataway, 
NJ). 
Unless stated otherwise, affinity purification tags were removed from all proteins 
by proteolysis before use in these experiments. Tobacco Etch Virus (TEV) protease 
(expressed in E. coli from pRK793, a derivate of BL21(DE3)-RIL, generously supplied 
by Dr. David S. Waugh  at the Center for Cancer Research at the National Cancer 
Institute) was used for HO-1 and thrombin was used for HO-2, CPR, and BVR. The 
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affinity tags were separated from the protein by chromatography with the appropriate 
affinity resin (Ni-NTA for HO-1, HO-2 and CPR; Glutathione Sepharose for BVR). All 
purification steps were performed at 4°C. 
The cDNA for human full-length HO-1 was graciously supplied by Dr. Ortiz de 
Montellano (University of California, San Francisco, CA). The LIC expression vector 
pMCSG10 was donated by Dr. William Clay Brown (University of Michigan, Ann Arbor, 
MI). Human full-length HO-2 cDNA in a pGEX-4T-2 vector was generously contributed 
by Dr. Mahin D. Maines (University of Rochester, School of Medicine, Rochester, NY) 
and was subcloned into the pET28a(+) expression vector. CPR was kindly donated by 
Dr. Bettie Sue Masters (University of Texas Health Sciences Center, Arlington, TX). The 
BVR gene was purchased from American Type Culture Collection (Manassas, VA) and 
subcloned into the pGEX-4T-2 plasmid.  
2.3.3 Site-directed mutageneisis of HO-1 and HO-2 
 Single-site substitutions of HO-1 and HO-2 were constructed using the 
QuickChange site-directed mutagenesis protocol (Stratagene, La Jolla, CA). 
Oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, Iowa). 
Positive transformants were enriched by antibiotic selection and confirmed using 
sequence analysis. All of the variants were purified exactly as described above for the 
wild type enzymes.  
2.3.4 Preparation of NMR samples 
 BL21(DE3) cells containing the pET28a(+)/HO-2 plasmid were cultured in M9 
minimal media with 1.0 g/L 15NH4Cl (Cambridge Isotopes, Tewksbury, MA, USA) to 
achieve 15N labeling of the soluble HO-2 protein. HO-2 was purified as described above 
and loaded with heme by titration of freshly prepared hemin. Hemin stocks were 
prepared by solubilizing hemin in 15% dimethyl sulfoxide (DMSO), 0.1 M NaOH, 50 mM 
Tris pH 7.0. Hemin stocks were centrifuged at 17,000 x g for 10 min at 4°C and the 
supernatant was then passed through a 0.22 micron filter (Millipore, Billerica, MA) to 
remove insoluble matter. Hemin concentration was determined using an Σ385nm of 58.44 
mM-1(43). HO-2 was loaded with hemin by titrating in small amounts of hemin and 
monitoring the Soret peak at 404 nm until saturating levels of heme binding were 
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achieved. NMR samples were prepared with 150 µM heme-bound HO-2 in 50 mM Tris-
HCl pH 7.0, 50 mM KCl with 10% D2O in a total volume of 350 µl and placed in a 
Shigemi NMR tube. Experiments testing the ability of CPR or BVR to bind HO-2 were 
conducted with 150 µM HO-2 and the binding partner (BVR or CPR) at the indicated 
concentration. 
1H-15N apoHO-2 NMR TROSY samples were prepared identically to those 
described for hHO-2, however heme was absent from the samples. 
For perdeuterated 15N-HO-2, samples were prepared as described above, 
however BL21(DE3) cells were grown and induced in 2H2O-M9 minimal media. 
Electrospray ionization mass spectrometry analysis revealed label incorporation to be 
99.8%. 
2.3.5 1H-15N TROSY NMR measurements 
 Two-dimensional 1H-15N HSQC TROSY spectra were acquired on an 
Agilent/Varian 800 MHz spectrometer equipped with a triple resonance gradient (PFG) 
cryo probe operating at 30°C. Spectra were acquired using an array of 2404 x 300 
complex points and with the spectral widths of 12019.2 Hz and 2999.9 Hz for 1H and 
15N respectively. All spectra were processed with NMRPipe software (44) and visualized 
using Sparky 3.114 (45). Intensity analysis was conducted as described (46); the peak 
heights of chemical shifts were derived from Sparky and used to calculate the ratio of 
resonance height for the 1H- 15N HO-2 spectrum with and without CPR or BVR. The 
chemical shift perturbation (CSP) for the assigned crosspeaks was measured between 
the 0 µM CPR spectrum and the 75 or 150 µM CPR spectrum for the perdeuterated 15N-
hHO-2 TROSY spectrum. CSPs were calculated from the square root of the sum of the 
squared N1H and 15N CSPs for each assigned cross peak.  
2.3.6 Determination of HO-2 molecular mass by NMR relaxation experiments 
 The experiments for studying the 15N NMR relaxation of HO-2 were carried out 
using a 40 µM HO-2 sample that was 15N labeled, in 50 mM Tris-HCl, 50 mM KCl pH 
7.0, recorded at 30 °C on a Agilent/Varian 800 MHz NMR System, using a cryo probe.  
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1D versions of the standard 15N R1 and 15N R2 HSQC experiments (with cross 
correlation, but with without Rex suppression) were carried out (47). In these 
experiments, amide proton magnetization is transferred to the amide 15N, where it is 
allowed to decay according to 15N R1 or R2 relaxation mechanisms, and transferred 
back to the amide proton for observation. R2 relaxation is faster for larger than for 
smaller molecules; R1 relaxation is slower for larger than for smaller molecules. From 
the ratio one may calculate the rotational correlation time. For spherical, rigid proteins, 
the rotational correlation time is proportional to the molecular weight. The data was 
processed in NMR pipe, and exported in text format using the Pipe2txt.tcl routine. The 
data were then imported into Microsoft Excel. For each spectrum, the ranges 8.7-9.0 
ppm (structured core residues) were integrated and the data were fit to a single 
exponential decay curve using in-house written non-linear least square fit code with 
jackknife error estimation (48).  
2.3.7 Steady-state kinetic analysis of HO-1, HO-2 and variants 
 The HO enzymatic assay was modified from previously described methods 
(49,50). Recent studies establish that catalase enhances the linearity of the membrane-
bound HO-1-catalyzed reaction (50). In our soluble system, we found a similar benefit of 
catalase for both HO-1 and HO-2 and therefore included it in the enzymatic assays. The 
200 µl reaction contained 0.1 µM HO, 15 µM heme, 0.35 µM BVR, 0.25 µg/µl BSA, 20 
U/µl catalase and varying concentrations of CPR in reaction buffer (50 mM Tris-HCl, pH 
8.0, 50 mM KCl). The reaction was incubated at 37°C for 2 minutes and then initiated 
with the addition of 8 µl of 10mM NADPH. Activity was monitored using a Shimadzu UV-
2600 spectrophotometer by following the increase in bilirubin absorbance at 468 nm. 
The difference extinction coefficient between heme and bilirubin at 468 nm of 43 mM-1 
cm-1 was used.  
2.3.8 Size exclusion chromatography analysis of HO-1, HO-2, and CPR 
 For gel filtration experiments, proteins were dialyzed into buffer containing 50 
mM Tris-HCl, pH 7.0, 50 mM KCl. After recovery from the dialysis tubing, samples were 
prepared with 50 µM of the indicated protein, 150 µM heme and 150 µM NADP+. Gel 
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filtration was conducted with a Shimadzu HPLC with an LC-10AT pump system using a 
Shodex KW-803 column (Shodex, Torrance, CA). The column was calibrated using gel 
filtration standards (BioRad, Hercules, CA) and the void volume was determined using 
blue dextran (2,000 kDa, Sigma, St Louis, MO). 
2.3.9 Surface Plasmon Resonance with HO-1, HO-2, and CPR  
 SPR binding experiments were conducted using a BIAcore 2000 (GE Healthcare, 
Pittsburgh, PA) at 25°C in 50 mM Tris pH 7.0, 50 mM KCl with 0.005% surfactant p20. 
HO-1 or HO-2 was immobilized directly to the dextran matrix of a research grade CM5 
sensor chip by amine coupling according to the manufacturers instructions (GE 
Healthcare, Pittsburgh, PA). The sensor chip surface was activated with NHS/EDC for 7 
minutes. Immobilized proteins were diluted to 0.001 µg/µl with 10 mM sodium acetate 
pH 4.5 and injected over the sensor chip surface. To minimize nonspecific binding and 
mass transfer immobilization levels were kept below 1000 RU. HO-1 and HO-2 were 
immobilized to 900 and 300 RU, respectively. 
For kinetic analysis of CPR and HO, 45 µl of varying concentrations of CPR were 
injected at a flow rate of 20 µl/min. Chip regeneration was conducted with a 5 µl 
injection of 0.5 mM NaCl. A blank reference cell was subtracted from the experimental 
data. To determine kinetic parameters, three independent experiments were initially 
analyzed using BIAevaluation software (GE Healthcare) and fit to a 1:1 Langmuir 
binding model or a bivalent analyte model. Because these models fit the data poorly, 
the association phase of CPR binding to HO was analyzed using single exponential fits 
(GraphPad 6.0). Kinetic constants were determined from the linear regression of kobs 
values plotted against CPR concentration. 
For experiments with immobilized CPR, human CPR was immobilized to the 
CM5 chip according to previously described methods for immobilization of rat CPR (24). 
Briefly, CPR was immobilized via thiol groups of cysteine residues with the coupling 
reagent 2-(2-pyridinyldithio)ethaneamine). To stabilize the enzyme and protect residues 
near the NADPH binding site, NADPH was included during the immobilization of CPR. 
CPR was immobilized to ~2000 response units. Others have reported that modification 
of CPR by 2-(2-pyridinyldithio)ethaneamine) does not affect enzyme activity (24). 
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Binding analysis with immobilized CPR was performed identically to those described 
above, with freshly prepared hemin as the soluble analyte. 
2.3.10 Sedimentation velocity analysis of HO-2 and CPR 
 Binding interactions between HO-2 and CPR were analyzed by sedimentation 
velocity experiments using a method described previously (51). Sedimentation velocity 
experiments were performed on an Optima XL-I analytical ultracentrifuge (Beckman 
coulter, Inc.) equipped with an eight-hole An50Ti rotor. Prior to analysis, HO-2 and CPR 
were dialyzed against 50 mM Tris pH 8.0 containing 150 mM NaCl. CPR (20.5 µM) was 
then mixed with increasing concentrations of HO-2 (0-55 µM) and the resulting protein 
mixtures (400 µl) were loaded into the sample compartment of a double-sector cell. The 
reference compartment was filled with 430 µl of the dialysate buffer. Sample cells were 
then incubated at 20oC in the rotor chamber for 2 h under vacuum. After 2 h of 
incubation, samples were sedimented at 40,000 rpm. A total of 180 absorbance scans 
(450 nm) at 3 min intervals were collected. Absorbance values ranged from 0.2-0.8 for 
the different samples. The data were analyzed by SEDFIT version 10.58d (52) using the 
continuous c(s) distribution model and allowing the frictional ratio to float. CPR-/HO-2 
interactions were monitored by integrating the c(s) distribution between 4 and 7 S to 
determine the weight-average s-value of the new observed boundary component (51). A 
Kd value for the CPR/HO-2 complex was estimated by plotting the weight-average s-
value as a function of HO-2 and fitting the data to a single-site binding isotherm. 
2.3.11 Chemical cross-linking of HO-1 and HO-2 with CPR, BVR or RNase 
 The reducible, heterobifunctional cross-linker (succinimidyl 6-(3-[2-pyridyldithio]-
propionamido)hexanoate) (LC-SPDP) was used in a two-step reaction according to the 
manufacturer’s instructions (Thermo Scientific/Pierce, Rockford, IL). HO-1 or HO-2 was 
activated as follows: a fresh 3 mM solution of LC-SPDP was prepared in DMSO. 10 µM 
HO-1 or HO-2 was prepared in conjugation buffer (0.1 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), pH 7.5, 30 mM ethylenediaminetetraacetic acid 
(EDTA), 150 mM NaCl) and incubated with 0.1 mM LC-SPDP for 30 min at room 
temperature. Unconjugated cross-linker was then removed by 3 rounds of buffer 
exchange using 10,000 MWCO Amicon microconcentrators (Millipore, Billerica, MA). 10 
 30 
µM BVR, CPR, or RNase was then added to the activated protein and the reaction was 
incubated at 4°C overnight. Cross-linking reactions were analyzed by 5-15% gradient 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) (BioRad, 
Berkeley, CA) and visualized by staining the gel with Coomassie blue (53).  
2.3.12 Co-purification of BVR with HO-2 
 For the co-purification of BVR with HO-2, the cross-linking reaction was 
performed exactly as described above, however HO-2 contained an N-terminal 6xHis 
tag (hisHO-2) that was absent in the other reactions. By SDS-PAGE, the cross-linked 
products of the reaction containing hisHO-2 and BVR migrated to identical positions as 
those in which the 6xHis tag had been removed from HO-2. Samples of hisHO-2 alone, 
BVR alone, or cross-linked hisHO-2/BVR were incubated with 100 µl of Ni NTA resin 
(50% slurry) for 2 hours at 4°C. Samples were rotated on a Boekel variable speed mini-
tube rotator (Fisher Scientific, Pittsburgh, PA). Affinity resin and associated proteins 
were harvested by centrifugation for 5 minutes at a setting of 2,400 x g at 4°C with an 
accuSpin Micro 17R refrigerated microcentrifuge (Fisher Scientific, Pittsburgh, PA) and 
washed three times with 1 ml of wash buffer (50 mM Tris-HCl pH 8.0, 30 mM NaCl, 20 
mM imidazole). Protein bound to the resin was eluted with 50 mM Tris-HCl, pH 8.0, 30 
mM NaCl, 300 mM imidazole. Eluted fractions were boiled for 5 minutes in SDS-PAGE 
loading buffer (50 mM Tris-HCL, pH 6.8, 2% (w/v) SDS, 0.1% (w/v) bromophenol blue, 
10% (v/v) glycerol, and 100 mM dithiothreitol) and separated by 10% SDS PAGE (53). 
Proteins were then transferred to a nitrocellulose membrane and detected using 
antibodies against either HO-2 (18) or BVR (Abcam, Cambridge, MA). 
2.3.13 Modification of BVR with CPM 
 Human BVR was modified with 7-diethylamino-3-(4'-maleimidylphenyl)-4-
methylcoumarin (CPM) according to methods used to modify rat BVR (27). A 20 mM 
solution of CPM was prepared in dimethyl sulfoxide. 10 µM BVR with 1 mM NADPH 
was incubated in the dark with 100 µM CPM at 4°C for 16 h. Free CPM was removed 
using a PD-10 desalting column (Amersham, Buckinghamshire, England). Labeled BVR 
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was then frozen and stored in the dark at -80°C. BVR-CPM was analyzed by LC MS/MS 
to determine the location of the CPM modification. 
2.3.14 Fluorescence resonance energy transfer (FRET): Analysis of the interaction 
of HO-1 or HO-2 with BVR 
 FRET experiments to examine HO-1 or HO-2 binding to human BVR were 
conducted according to previously described methods for rat BVR (27). Briefly, because 
the UV-visible spectra of heme-bound HO-1 and HO-2 overlap the fluorescence 
emission spectrum of the fluorescent probe CPM, binding of heme bound HO should 
result in fluorescence quenching of BVR-CPM. BVR-CPM (0.05 µM) was titrated with 
various concentrations of heme-bound HO-1, heme-bound HO-2, or heme, and 
fluorescence was monitored at 450 nm with excitation at 350 nm. These experiments 
were performed in 0.1 M potassium phosphate buffer at pH 7.4 on a Shimadzu FR-
5301PC spectrofluorophotometer. 
2.3.15 Heme binding BVR by optical absorbance 
 To obtain the absorbance spectrum of heme BVR, the difference spectra 
between 350 and 700 nm was recorded for 2.5 µM BVR with 2.0 µM heme, while the 
reference cuvette contained 2.5 µM BVR alone. To determine binding affinity of heme 
for BVR, 10 µM hemin was titrated with increasing amounts of BVR (0.5 - 5.0 µM) with 
10 µM heme alone in the reference cuvette. Absorbance at 415 nm vs BVR 
concentration was fit to a single site binding model using GraphPad Prism 6.0. To asses 
the ability of BVR to bind heme from hHO-2, 5 µM of hHO-2 was incubated with varying 
concentrations of BVR (1.0 – 20.0 µM) and the absorbance spectra from 250 - 700 nm 
was collected, with the reference cuvette containing 5 µM hHO-2. hHO-2 was prepared 
by incubating apoHO-2 with a 5-fold excess of freshly prepared hemin for 1 h at 4°C. 
Unbound heme was removed using a PD 10 desalting colum according to the 
manufacturers instructions (GE healthcare). For all experiments fresh hemin was used, 
prepared as described above. All spectra were collected on a Shimadzu UV-2600 
spectrophotometer. 
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2.4 Experimental results 
Various forms of HO and CPR lacking their transmembrane segments were used 
in these studies. These are HO-1(1-265) containing residues 1-265, HO-2(1-288) and 
CPR(66-680). For clarity, these proteins will be referred to simply as HO-1, HO-2 or 
CPR. In experiments that use heme-bound HO, we refer to the protein as hHO-1 or 
hHO-2. 
2.4.1 NMR analysis of the interaction between hHO-2 and CPR 
 Nuclear magnetic resonance (NMR) is a highly sensitive method to probe 
protein-protein interactions. Binding of an NMR-silent protein to an NMR-visible protein 
can perturb the spectrum in several ways: it can change the chemical shift, alter the line 
width of a resonance, or affect both chemical shift and line width. If resonances within 
the NMR spectrum have been assigned, these spectral changes can provide residue-
specific information regarding the interface between the two proteins.  
We recently assigned 70% of the backbone chemical shifts of the hHO-2 (heme 
bound) NMR spectrum by 3D NMR experiments using a highly concentrated sample (1 
mM) (Bagai, Ragsdale & Zuiderweg, in preparation). To avoid potential non-specific 
interaction effects that could arise with highly concentrated protein, in the binding 
studies described here, we used 150 µM 15N hHO-2 samples. Because large proteins 
such as HO-2 (~33 kDa) tend to exhibit faster transverse relaxation that reduces signal 
intensity of the NMR spectrum, we utilized transverse relaxation-optimized spectroscopy 
(TROSY). TROSY is a method that reduces the 1H and 15N resonance linewidths to 
enhance the spectra of larger proteins (>30 kDa) (54). By applying TROSY, we observe 
211 cross peaks in the 1H-15N TROSY spectrum of perdeuterated 15N-hHO-2, which 
accounts for resonances arising from ~70% of the hHO-2 residues (Figure 2.2). The 
hHO-2 spectrum consists of resonances arising from both ordered and disordered 
regions of the protein. Amide proton resonances arising from disordered regions of HO-
2 occur in the 7.7-8.6 ppm range, which has a high density of overlapping peaks 
characteristic of poorly structured regions (46). This region of the spectrum corresponds 
to the flexible N- and C- terminal domains of hHO-2; residues 1–28 and 243-288. The 
well-dispersed peaks outside of the disordered region arise from the core of hHO-2, as 
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highlighted by the annotated spectra (Figure 2.2) (Bagai, Ragsdale & Zuiderweg, in 
preparation). Also, in the crystal structure of HO-2 (PDB 2QPP) only the catalytic core of 
the protein (residues 29-242) is visible, and both the N- and C- termini are not observed, 
further supporting the flexibility of the N- and C- termini (55). 
 
 
Figure 2.2. NMR analysis of CPR binding hHO-2. 1H-15N TROSY spectra of 150 µM 
perdeuterated 15N-hHO-2 collected in the absence (black) or presence (red) of 
equimolar CPR. 
 
To probe the interface between hHO-2 and CPR, we collected the spectrum of 
perdeuterated 15N-hHO-2 in the presence or absence of natural abundance CPR 
(lacking any label). As noted above, we used a lower concentration of hHO-2 (150 µM) 
than was used earlier to make the assignments in order to minimize the potential for 
non-specific effects such as aggregation. We overlayed the assigned HO-2 spectrum 
with that collected in the binding studies to determine assignments for the spectrum in 
the binding studies. Using this method, ~50% of the 288 HO-2 residues in the binding 
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study could be assigned. Analysis of the HO-2 spectrum described below will focus on 
the assigned region of the protein. 
We measured the chemical shift and peak height for resonances in the hHO-2 
TROSY spectrum in the presence and absence of CPR. To identify hHO-2 residues that 
are affected by CPR, we compared the 1H- 15N TROSY spectrum of hHO-2 in the 
presence of equimolar unlabeled CPR to that of hHO-2 alone. The addition of CPR to 
hHO-2 causes changes in hHO-2 chemical shifts and also decreases in peak intensities 
for a number of hHO-2 residues (Figure 2.2). This peak intensity loss is consistent with 
an increase in molecular weight and concomitant reduction of TROSY intensity that we 
would expect to occur as hHO-2 molecular weight increases with the binding of a 70 
kDa protein such as CPR (46,56).  
The addition of CPR to hHO-2 also results in chemical shift perturbations (CSPs) 
for some hHO-2 cross peaks (Figure 2.3). This demonstrates that the kinetics of binding 
is in the fast or intermediate fast exchange for which the resonance position  of a 
certain residue i is given by (57)  
 
   [Equation 3] 
 
where ffree and fbound are the molar fractions of free and complexed HO-2 and where 
 and bound are the chemical shifts in radians of that resonance in those 
states. The equation holds for both 1H and 15N dimensions in the TROSY spectrum.  
 
ω i
obs
ω i
obs = f freeω ifree + fboundω ibound
ω i
free ω i
bound
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Figure 2.3. The effect of CPR on hHO-2 chemical shifts. Detail of the 1H-15N hHO-2 
spectrum with 0, 75, or 150 µM CPR (black, blue, and red respectively) highlighting 
cross peaks that experience significant perturbations of the chemical shift or significant 
intensity loss. E182 and D210 show highly significant change in chemical shifts, while 
L81 is broadened beyond detection with the addition of CPR. “x” represents the center 
of the indicated cross peak. Highly significant changes in CSP are greater than 2 
standard deviations from the mean CSP for assigned residues. 
 
 To quantify CSPs, the 1H and 15N chemical shift difference was calculated by 
comparing the chemical shifts of hHO-2 alone to those with CPR. The combined 15N/NH 
chemical shift change was calculated as the chemical shift change vector as described 
in the Experimental Methods. Of the 47 assigned cross peaks in the N- and C- termini, 
non exhibit significant CSPs with the addition of equimolar CPR; however 28 residues of 
the 96 assigned residues from the HO-2 core exhibit significant CSPs (~30%) (Figure 
2.4). Mapping the residues with significant CSPs onto the hHO-2 crystal structure 
highlights contiguous patches of residues on HO-2 that are likely involved in binding 
CPR or experience allosteric effects upon CPR binding (Figure 2.5) Equally important, 
there are also many assigned resonances that do not shift, and they also form 
contiguous patches. 
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Figure 2.4. The effect of CPR on hHO-2 chemical shifts. Histogram bars represent 
the combined 15N/NH chemical shift perturbation (CSP) for assigned residues in the 
hHO-2 spectrum in the presence of 75 µM or 150 µM CPR (white or grey respectively). 
The CSP for the assigned cross peaks, measured between the 0 µM CPR spectrum 
and the 75 or 150 µM CPR spectrum, was calculated from the square root of the sum of 
the squared N1H and 15N CSPs. Cross peaks that have broadened beyond detection 
with the addition of CPR are shown as black bars of uniform height. Dotted lines 
indicate CSPs that are significant (1 standard deviation from the mean) or very 
significant (2 standard deviations from the mean). Bars with greyed labels represent 
resonances that are unassigned, while assigned residues are in black. 
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Figure 2.5. CPR induced CSPs on the hHO-2 spectrum mapped onto the crystal 
structure. The effect of 75 or 150 µM CPR ((A), and (B) respectively) on hHO-2 CSPs 
as determined in Figure 2.4 mapped on to the crystal structure of hHO-2 (PDB 2QPP). 
The color of the residue reflects the degree of CSP effect by CPR. Red: residues with 
highly significant CSPs (more than two standard deviations from the mean); Orange: 
residues with significant CSPs (at least one standard deviation from the mean); Blue: 
residues with no significant CSP; White: residues that are broadened beyond detection; 
Grey: residues that are unassigned. 
 
For the range 0.1 < ffree or fbound < 0.9, the linewidth  for a resonance i in 
the fast/ intermediate exchange regime is given by Equation 4 (57). 
 𝐿𝑊!!"# = 𝑓!"##𝐿𝑊!!"## +   𝑓!"#$%𝐿𝑊!!"#$% + 𝑓!"##  𝑓!"#$% (!!!"##!!!!"#$%)!(!!  !!"#$% !!"##)!!""        [Equation 4] 
 
Here, the first two terms represent the increase in linewidth due to a change in 
the time-averaged molecular weight of HO-2, while the latter term, called exchange 
broadening, is excess broadening due to the kinetics of binding.  
The increase in linewidth causes a loss in TROSY cross peak height by two 
processes: the first is a linear effect and occurs because a broader line in the spectrum 
LWiobs
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has a lower peak height; the second is a strongly non-linear effect due to a decrease in 
the coherence transfer efficiencies in the TROSY experiment itself. For large proteins 
that bind to other large proteins, the second effect is dominant. 
To quantify the peak intensity loss in the hHO-2 spectrum upon CPR binding, the 
peak intensity ratio was determined by dividing the cross peak intensity in the presence 
of CPR by the cross peak intensity from the hHO-2 alone spectrum (+CPR/-CPR) 
(Figure 2.6). A ratio of 1 indicates no effect, while a decreased ratio indicates line 
broadening for that resonance. Cross peaks deriving from residues located at the HO-2 
N- and C-termini (residues 1-28 and 243-288) are largely unaffected by the addition of 
equimolar CPR; of the 47 assigned cross peaks, only 4 exhibit chemical shift intensity 
ratios of less than 0.8 (G20, A245, and E247). This is in contrast to the 96 assigned 
cross peaks located at the core of HO-2 (residues 29-242); 88 resonances exhibit an 
intensity ratio of less than 0.8 and 23 have disappeared likely due to broadening beyond 
detection (Figure 2.6). Mapping the intensity ratios onto the hHO-2 crystal structure 
shows the residues that are most strongly affected by CPR are on the heme binding 
face of hHO-2 (in which the heme binding pocket and surrounding residues are visible), 
while residues on the opposite face (180° rotation) of hHO-2 are less affected (Figure 
2.7).  
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Figure 2.6. The effect of CPR on perdeuterated hHO-2 chemical shift intensities. 
Histogram bars represent the ratio of peak height in the absence or presence of CPR 
(+CPR/-CPR).  Ratios with 75, and 150 µM CPR are shown (white and grey, 
respectively).  A ratio of 1 (dotted line) indicates no change for that residue. Negative 
bars represent cross peaks that are broadened beyond detection with the addition of 
CPR. Bars that are absent represent residues that are unassigned in the spectrum. 
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Figure 2.7. CPR induced changes for hHO-2 cross peak intensities mapped onto 
the crystal structure. The effect of 75 or 150 µM CPR ((A), and (B) respectively) on 
hHO-2 cross peak heights mapped on to the crystal structure of hHO-2 (PDB 2QPP). 
Cross peak intensity ratios are as determined in Figure 2.6. The color of the residue 
reflects the degree of effect by CPR. Red: ratio of 0 < 0.2; Orange: ratio of 0.2 < 0.3; 
Blue: ratio > 0.3; White: residues that are broadened beyond detection; Grey: residues 
that are unassigned. 
 
 The interaction areas determined from intensity changes (Figure 2.5) and 
chemical shift changes (Figure 2.7) do overlap in general, suggesting the main binding 
area is identified by both observables. However, the intensity changes and chemical 
shifts do not correlate per residue. The most compelling case occurs for the resonance 
of L201, which completely disappears while large changes in chemical shift are not 
observed. As discussed below, this discrepancy indicates a complex binding 
mechanism. 
2.4.2 A titration of CPR into hHO-2 by NMR 
 If the effects of CPR on the hHO-2 spectrum are due to CPR binding, changes 
induced by CPR should be titratable. Thus, additional experiments were conducted with 
50 µM, 150 µM, 200 µM, and 300 µM CPR and the resonance height ratio calculated as 
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described above (Figure 2.8 and Figure 2.9). Under these conditions, using hHO-2 that 
was not perdeuterated, we observe 165 cross peaks in the 1H- 15N hHO-2 spectrum, 
which accounts for resonances arising from ~60% of the hHO-2 residues. Comparison 
of these spectra with the assigned spectrum allows for assignment of 36% of 288 HO-2 
residues (Figure 2.9).  
 
 
Figure 2.8. NMR analysis of CPR binding non-perdeuterated 15N hHO-2. 1H- 15N 
TROSY spectra of 150 µM non-perdeuterated 15N-hHO-2 collected in the absence 
(black) or presence (red) of equimolar CPR. 
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Figure 2.9. The effect of various concentrations of CPR on non-perdeuterated 15N-
hHO-2 resonances. Histogram bars represent the ratio of resonance height in the 
absence or presence of CPR (+CPR/-CPR). Ratios with 50, 150, 200 and 300 µM CPR 
are shown (black, light grey, dark grey and white bars respectively).  A ratio of 1 (dotted 
line) indicates no change for that residue.  Bars that are absent (greyed label) represent 
resonances that are unassigned, while assigned residues are in bold. The asterisk 
highlights L201 as the cross peak that is most sensitive to the addition of CPR. 
 
To quantify the effects of CPR on hHO-2 residues, we compared the 1H- 15N 
TROSY spectrum of hHO-2 in the presence of CPR to that of hHO-2 alone. While the 
addition of CPR to hHO-2 does not cause observable changes in hHO-2 chemical shifts 
in the TROSY spectrum for non-perdeuterated hHO-2, a decrease in peak intensity for a 
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number of hHO-2 residues proportional to the concentration of CPR is observed (Figure 
2.9). Although titratable changes in the HO-2 spectrum could conceivably result from 
CPR-dependent catalytic activity of HO-2, this is unlikely to be the cause of the 
observed intensity changes because NADPH in not present in the NMR experiment and 
HO-2 is inactive in its absence. Furthermore, CPR causes similar peak height reduction 
for the apoHO-2 spectrum – here substrate and reducing equivalents are both absent, 
preventing any catalytic turnover.  
Of the assigned residues in the hHO-2 spectrum, the residue that is most 
affected by the addition of equimolar concentrations of CPR is L201; cross peak hight is 
most strongly affected by CPR even at the lowest concentration of CPR (50 μM). E107, 
A208, L209, L211 and L33 are also strongly affected. While in our 150 µM NMR sample 
we do not have consecutive assignments for these residues, in the more concentrated 
multi-dimensional experiments used for assigning the hHO-2 spectrum L201, A208, 
L209, and L211 are part of a consecutively assigned region E190-N212. L33 is part of a 
consecutively assigned region from R29-L37 and E107 is part of a consecutively 
assigned region from E107-L109, so the assignments are quite secure. 
We also conducted 15N T2 and T1 relaxation experiments to estimate the 
molecular mass of hHO-2 under the NMR conditions. The rotational correlation time of a 
protein is linearly related to its molecular weight; therefore, 15N spin relaxation rates can 
be used to determine the molecular weight of a protein in solution (58). The molecular 
mass estimate for the hHO-2 core is found to be 55 kDa. The mass of monomeric hHO-
2 (1-288) is 33 kDa and that of the hHO-2 core (29-242) is 25 kDa. Thus, the NMR 
relaxation experiments indicate that hHO-2 is a dimer under the present conditions (> 
40 µM protein).  
2.4.3 NMR analysis of the interaction between apoHO-2 and CPR 
 To test the ability of CPR to bind apoHO-2, the 1H- 15N spectrum of 500 µM non-
perdeuterated 15N-apoHO-2 was collected in the presence or absence of 100 µM CPR, 
as described for hHO-2. The addition of CPR to apoHO-2 causes a loss of intensity for 
apoHO-2 cross peaks similar to what is observed in the hHO-2 spectrum (Figure 2.10). 
In the apoHO-2 spectrum, 121 distinct cross peaks are visible, representing ~40% of 
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HO-2 residues. While assignments for the apoHO-2 spectrum have not been 
determined, changes in chemical shift intensity were quantified by calculating the 
chemical shift height ratio (+CPR/-CPR) for each of the cross peaks. Of the 121 distinct 
cross peaks analyzed in the apoHO-2 spectrum, 19 exhibit a chemical shift height ratio 
of less than 0.8, indicating a loss of cross peak height for the corresponding HO-2 
residues. Changes in chemical shift are not observed for any cross peaks in the non-
perdeuterated spectra. These data indicate that CPR is capable of binding apoHO-2 as 
well as hHO-2. 
Assignments have not been independently determined for the apoHO-2 TROSY 
spectrum and the spectrum is distinct from that of hHO-2 (Figure 2.11). However, some 
isolated cross peaks of the hHO-2 spectrum have identical chemical shifts as in the 
apoHO-2 spectrum, allowing for a reasonable assignment of the apoHO-2 cross peak 
from the hHO-2 spectrum, notably L201 (Figure 2.11). Strikingly, of the 121 cross peaks 
analyzed, the cross peak at the location of L201 in the apoHO-2 spectrum is the most 
sensitive to the addition of CPR, similar to what is observed for the hHO-2 spectrum. 
 
Figure 2.10. NMR analysis of CPR binding apoHO-2. 1H-15N TROSY spectra of 500 
µM non-perdeuterated 15N-apoHO-2 collected in the absence (black) or presence (red) 
of 100 µM CPR. 
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Figure 2.11. TROSY spectra of hHO-2 (black) and apoHO-2 (red). 1H-15N TROSY 
spectra of 150 µM non-perdeuterated15N-hHO-2 (black) or 500 µM non-perdeuterated 
apoHO-2 (red). The cross peak assigned as L201 for the hHO-2 spectrum is identified. 
 
2.4.4 Steady-state kinetic analysis of HO-1 and HO-2 mutants 
 Residues that exhibit large changes in the hHO-2 NMR spectrum upon binding 
CPR could be present at the interface of HO-2 and CPR, or alternatively, they could 
change their chemical environment due to long-range conformational changes in HO-2 
induced by CPR binding at a distant site. In the CPR titration experiments using non-
perdueterated HO-2, at all CPR concentrations L201 exhibits the greatest loss of cross 
peak height compared with the other assigned cross peaks (e.g. a low cross peak 
height ratio). In the apoHO-2/CPR binding studies L201 is also exhibits the largest loss 
of cross peak height. Therefore, of the assigned residues in the HO-2 spectrum, we 
consider L201 to be the most sensitive to the addition of CPR. 
 Based on the hypothesis that mutation of residues at the HO-2/CPR interface 
would lead to an increase in Kd for the HO-2/CPR complex and, thus, an increased Km 
 46 
value for CPR, we tested the effect of alanine substitutions on steady-state kinetic 
parameters for L201 and K169, which were expected to exhibit higher Km values, and 
R87, which was used as a control. If a residue exhibits changes in the NMR spectrum 
by indirect effects (e.g., due to a conformational change), making a conservative 
mutation of that residue is unlikely to affect the Kd or Km values. Also, we note that HO-2 
is likely a homodimer in the NMR binding studies. If a resonance is affected by a 
change in HO-2 dimerization state, a mutation of that residue would be unlikely to effect 
the kinetic parameters of HO-2 and CPR.  
Alanine substitution of the HO-2 residue with the cross peak intensity that is most 
strongly affected by equimolar CPR in the non-perdeuterated NMR binding studies 
(Figure 2.9), L201A, results in a 3-fold increase in the Km for CPR and no change in kcat 
compared to wild-type protein (Figure 2.12B, Table 2.1). On the other hand, the R87A 
variant of HO-2, whose NMR cross peak height is not strongly affected by the addition 
of CPR, exhibits no change in the kcat or Km for CPR (Figure 2.12B, Table 2.1). These 
results are consistent with a role for L201 at the binding interface for CPR.  
We also studied the K169A variant of HO-2 because alanine substitution of 
K149, the analogous residue in HO-1, exhibits a 7-10-fold increase in Kd of the HO-
1/CPR complex (24,27). K169 is present on the heme binding face of HO-2. We 
observe a ~20-fold increase in the Km of the K169A variant of HO-2 for CPR and a 40-
fold increase in the Km value for the K149A variant of HO-1 (Figure 2.12, Table 2.1). 
These results indicate that this lysine residue of HO-2 and HO-1 is involved in binding 
CPR. 
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Figure 2.12. HO mutants have an increased Km for CPR. Heme oxygenase activity for 
HO-1 (A) or HO-2 (B) and their respective mutants with varying amounts of CPR.  
Activity was monitored by observing the formation of bilirubin at 468 nm, as described in 
the methods. 
 
 
 
 
Table 2.1. Michaelis parameters for HO variants and CPR. Heme oxygenase activity 
was monitored for HO-1 or HO-2 and the indicated mutants with varying amounts of 
CPR as shown in Figure 2.12.  Specific activity is represented as nmol bilirubin/min/mg 
HO. 
Construct Vmax Km Km 
 (nmolmin-1mg-1) (μM) (Fold Change) 
HO-1    
WT 370.1 ± 12.5 0.5 ± 0.1 1 
K149A 847 ± 64 21.7 ± 2.6 42.4 
HO-2    
WT 297 ± 5 0.7 ± 0.1 1 
R87A 275 ± 11 0.9 ± 0.1 1.3 
L201A 298.2 ± 8.0 2.3 ± 0.2 3.3 
K169A 416.9 ± 36.9 15.2 ± 2.6 21.7 
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2.4.5 Gel filtration analysis of the binding of hHO-1, hHO-2, and CPR 
 In an attempt to observe the complex between CPR and HO-2 (and HO-1) by 
other methods, we performed gel filtration experiments. Kd values ranging from ~0.5-2.0 
µM have been reported for hHO-1 and CPR, and NADP+ is reported to enhance binding 
(24,27). We performed gel filtration experiments with 50 µM HO-1 or HO-2 and 
equimolar CPR in the presence of 150 µM NADP+ and 150 µM hemin. For comparison, 
the elution of the individual proteins (HO-1, HO-2 and CPR) in the presence of heme 
and NADP+ was also determined. Because heme or NADP+ could affect the migration 
of the individual proteins, they were included in 3-fold excess in all samples.  
By gel filtration analyses, we did not observe any evidence for a complex 
between CPR and either hHO-1 or hHO-2 (Figure 2.13, Table 2.2). CPR migrates at 
position 1 (~70 kDa) in the absence (dashed line) or presence (red lines) of hHO-1 or 
hHO-2 (Figure 2.13). Peak 2, which marks the migration of hHO-2 or hHO-1, 
corresponds to ~60 kDa and 44 kDa, respectively, and shows up as a shoulder in 
Figure 2.13A in the HO-1/CPR sample. Consistent with the NMR relaxation studies, 
these results suggest that hHO-2 exists as a homodimer under these conditions. The 
difference in apparent mass between HO-1 and CPR is greater than that between HO-2 
and CPR; therefore peaks 1 and 2 are slightly separated in Figure 2.13A and are 
overlapped in Figure 2.13B. The elution profile of CPR was unaffected by incubation 
with either HO-1 or HO-2; for example, a CPR/HO-2 complex, which would have eluted 
at a position corresponding to ~100 kDa, was not observed. Others have also failed to 
observe a complex between wild type HO-1 and CPR by gel filtration (26). The HO/CPR 
complex is undetected under these conditions, suggesting that the complex is weak 
and/or highly transient, consistent with the NMR and steady-state kinetic studies.  
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Figure 2.13. HO and CPR analysis by size exclusion chromatography. 50 µM CPR 
and HO-1 (A) or CPR and HO-2 (B) were loaded onto a Shodex KW-803 gel filtration 
column individually or in the indicated mixture in the presence of 150 µM heme and 150 
µM NADP+ in running buffer (50 mM Tris, 50 mM KCl pH 7.0). The asterisk (*) 
represents the retention time for a 100 kDa protein and grey arrows mark the position of 
the molecular weight standards. Peak 1: CPR, peak 2: heme oxygenase, peak 3: 
NADP+ and heme, peak 4: HO-2 aggregate. 
 
 
 
Table 2.2. Apparent molecular weight of HO-1, HO-2, and CPR by gel filtration. 
Ve/Vo values for the indicated proteins, blue dextran (V0), B12, and protein standards 
(BioRad) were measured and the apparent masses were determined as described in 
the Experimental Procedures section. 
Protein Ve/V0 Apparent Mass (kDa) 
   
HO-1 1.565 ± 0.005 44.02 ± 1.67 
HO-2 1.525 ± 0.002 60.26 ± 1.15 
CPR 1.509 ± 0.004 68.63 ± 1.99 
CPR (with HO-1) 1.507 ± 0.004 69.60 ± 2.02 
CPR (with HO-2) 1.506 ± 0.002 70.00 ± 1.33 
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2.4.6 Binding of CPR to HO-1 or HO-2 by surface plasmon resonance (SPR) 
 We also attempted to quantify CPR binding to HO-1 and HO-2 using SPR, with 
HO-1 or HO-2 immobilized on the dextran surface of the SPR chip through amine 
chemistry (Figure 2.14). Representative association and dissociation curves with 
various concentrations of CPR (1.25 - 20 µM) are shown in Figure 2.14A. The SPR 
sensorgrams show CPR-dependent association and CPR-independent dissociation 
phases, clearly demonstrating that CPR binds to both HO-1 and HO-2. To avoid 
potential artifacts, these experiments were performed in the absence of heme because 
heme itself produced a strong “binding” response (Figure 2.14E). Use of the 
apoproteins is justified by our NMR experiments (above) using apoHO-2 and CPR, 
which clearly demonstrate that CPR can bind both apoHO-2 and hHO-2.  
To derive binding kinetic constants from the SPR sensorgrams, the association 
and dissociation phases were fit individually because simultaneous global fitting 
analysis of CPR association and dissociation curves using the 1:1 Langmuir model 
(BiaEvaluation) produces a poor fit to the data. Single exponential fits of the association 
phase (GraphPad Prism6) of CPR and HO-1 or HO-2 were used to determine kon values 
(0.0010 ± 0.0002 s-1µM-1 and 0.0014 ± 0.0002 s-1µM-1) and koff values (0.020 ± 0.003 s-1 
and 0.0230 ± 0.0003 s-1) for CPR binding to HO-1 or HO-2 respectively (Figure 2.14B 
and C). From these kon and koff values, Kd values of 20.5 ± 7.6 µM and 16.7 ± 2.5 µM 
were determined for CPR and HO-1 or HO-2, respectively, indicating that these proteins 
form relatively weak (transient) complexes. Biexponental fits of the dissociation curves 
(Figure 2.14D) indicate a fast and slow dissociation phase, with kfast values in 
reasonable agreement with the values determined by linear regression analysis of the 
binding data (kfast = 0.026 ± 0.002 and 0.035 ± 0.008 s-1; kslow = 0.0030 ± 0.0015 and 
0.0025 ± 0.0005 s-1 for HO-1 and HO-2 respectively). 
 
 51 
 
Figure 2.14. SPR analysis of CPR binding HO-1 (left) and HO-2 (right). (A) Various 
concentrations of CPR (1.25, 2.5, 5.0, 10.0 and 20.0 µM) were injected against 
immobilized HO-1 or HO-2. (B) Single exponential fits for the association phase of CPR 
binding HO-1 or HO-2 are shown in red. (C) Single exponential fits were used to 
determine kobs for the association phase of CPR binding HO-1 or HO-2. kon and koff 
values are derived from the linear regression of kobs (kon= slope; koff= y intercept). (D) 
Biexponential fits for the dissociation phase of CPR binding HO-1 or HO-2 are shown in 
red (E) Various concentrations of heme (0.125, 0.25, and 0.5 µM) were injected against 
immobilized CPR. Data are representative of three independent experiments.  
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2.4.7 Sedimentation velocity analysis of HO-2 and CPR 
 Binding interactions between CPR and HO-2 were also analyzed by 
sedimentation velocity ultracentrifugation, a method that is less sensitive to heme 
artifacts than SPR. As described in the methods, 20.5 µM CPR was titrated with varying 
concentrations of heme bound HO-2 (0-55 µM). In these experiments, the 
sedimentation coefficient distribution of CPR was monitored in the presence of 
increasing concentrations of hHO-2. Figure 2.15A shows a sedimentation velocity 
profile obtained with a 2:1 molar ratio of hHO-2 to CPR. In the absence of hHO-2, CPR 
is characterized by a sedimentation coefficient centered at 4.5 S as shown in Figure 
2.15B. hHO-2 alone shows two sedimentation coefficients with a major component 
(60%) centered at 2.8 S and a minor component (34%) at 4.2 S. Upon adding hHO-2, 
the shape of the CPR component changes with the boundary shifting to a higher 
sedimentation coefficient. The weight-average s-value of this fast boundary component 
was determined by integrating the c(s) distribution between 4 and 7 S. From these data, 
a Kd of 15.1 ± 6.5 µM was determined for hHO-2 and CPR. At the highest hHO-2 
concentration, the CPR/HO-2 complex was characterized by a weight-average s-value 
of 5.2 S. 
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Figure 2.15. Sedimentation velocity analysis of HO-2 and CPR interactions. (A) 
Velocity scans selected from analysis of a 2:1 ratio of hHO-2 (41 µM) to CPR (20.5 µM). 
Shown are the absorbance data (open circles) fitted (solid lines) to the continuous c(s) 
distribution model. (B) Sedimentation coefficient distributions of CPR (20.5 µM) alone 
(black trace) and in the presence of 4.1 µM (orange trace), 10.25 µM (blue trace), 
20.5 µM (red trace), 30.75 µM (purple trace), 41 µM (green trace), and 55 µM HO-2 
(gray trace). hHO-2 alone (41 µM) is shown in magenta. The inset shows the weight-
average s-value plotted versus HO-2 concentration. The data were fit to a single-site 
binding isotherm to yield a Kd value of 15.1 ± 6.5 µM. 
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2.4.8 Chemical cross-linking of CPR and HO-1 or HO-2 
 We conducted chemical cross-linking experiments to trap the complex between 
HO-2 and CPR. Because cross-linking is an irreversible reaction, even transient 
complexes can be detected. Because CPR has been reported to bind HO-1 (24-27), we 
used HO-1 and CPR as a positive control. According to the crystal structure (PDB 
3QE2), human CPR possesses at least two surface cysteine residues, which should be 
available for cross-linking. Thus, we utilized the heterobifunctional cross-linker LC-
SPDP, which contains both an amine and a thiol reactive group. As described in the 
Methods section, after activating HO-1 or HO-2 and removing unreacted cross-linker, 
CPR was added and the reaction was incubated overnight at 4°C. Stable complexes 
between CPR and HO-1 as well as CPR and HO-2 were formed (Figure 2.16). A small 
amount of HO-2 homodimer is visible in the HO-2 sample that lacks CPR, while, for 
activated HO-1 alone, no homodimeric complex was observed.  
As a negative control, we activated the HOs as described above and incubated 
with a physiologically unrelated cysteine containing protein, RNase, instead of CPR. 
RNase (based on PDB 1RCA) contains eight cysteine residues, four of which are 
surface exposed. No high-molecular weight complex between RNaseA and either HO-1 
or HO-2 was observed (Figure 2.16B). 
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Figure 2.16. Chemical crosslinking of HO-2 and CPR. (A) The heterobifunctional 
cross linker LC-SPDP stabilizes a complex between HO-1 or HO-2 and CPR. (B) No 
complex is trapped for HO-1 or HO-2 with RNAse.  (C) Chemical crosslinking also 
stabilizes a complex between HO-1 or HO-2 and BVR. (D) Reducing SDS-PAGE and 
Western blot of HO-2 pull down and associated BVR.  Lane 1: crosslinking reaction, 
Lane 2: HO-2 only, Lane 3: BVR only. Crosslinking reactions contained 10 µM of the 
indicated protein. A, B, and C are Coomassie stained non-reducing SDS PAGE 
analyses of the indicated reaction. 
 
2.4.9 NMR studies of HO-2 in the presence of BVR 
 BVR mediates the second step in heme degradation, the conversion of biliverdin 
to bilirubin. HO-1 and BVR are reported to form a complex with a Kd of 0.2 ± 0.1 µM 
(24,27). An overlapping binding site on HO-1 for CPR and BVR has been proposed, but 
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with the binding sites not identical (24,25,27). To our knowledge, binding of HO-2 and 
BVR has not been addressed. 
To attempt to characterize the binding interface between HO-2 and BVR, we 
performed NMR experiments similar to those described for HO-2 and CPR. The 1H- 15N 
TROSY spectrum of 150 µM non-perdeuterated 15N-hHO-2 was collected in the 
absence or presence of equimolar BVR (not labeled with 15N). While CPR induced 
obvious changes in the hHO-2 spectrum (Figure 2.8), the spectrum of hHO-2 collected 
in the presence of BVR is almost identical to that of hHO-2 alone (Figure 2.17). No 
changes in the chemical shifts are apparent and the majority of assigned resonances 
exhibit a height ratio (+BVR/-BVR) close to 1, indicating no change (Figure 2.18). These 
results suggest that under the NMR conditions (150 µM), BVR binds hHO-2 very 
weakly, if at all. Experiments with 15N-apoHO-2 and equimolar BVR also showed BVR 
has no effect on the apoHO-2 spectrum (data not shown). 
 Our NMR binding studies thus suggest that BVR has a significantly lower affinity 
for HO-2 compared with CPR. In contrast, others have reported nM Kd values for the 
BVR/hHO-1 complex (27). Because HO-1 and HO-2 are highly homologous, our results 
were unexpected. Thus, other experiments were performed to assess the interaction 
between the HO’s and BVR.  
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Figure 2.17. NMR analysis of BVR binding HO-2. 1H- 15N TROSY spectra of 150 µM 
non-perdeuterated 15N-hHO-2 collected in the absence (black) or presence (red) of 
equimolar BVR.   
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Figure 2.18. The effect of BVR on HO-2 resonances. The ratio of hHO-2 resonance 
height with and without equimolar BVR (+BVR/-BVR) is represented by the grey bars. A 
ratio of 1 (dotted line) indicates no change for that residue. Bars that are absent (greyed 
label) represent resonances that are unassigned while assigned residues are in bold. 
 
2.4.10 Fluorescence quenching experiments with BVR-CPM and HO-1 or HO-2 
 One possible explanation for the lack of NMR evidence for an HO-2/BVR 
interaction is that HO-2 interacts differently with BVR compared to HO-1. To address 
this possibility, we repeated the published fluorescence quenching experiments for 
measuring interactions between HO-1 and BVR (27) and performed similar experiments 
to determine the binding affinity of HO-2 for BVR. In these studies, BVR was labeled 
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with the thiol-reactive dye CPM to produce fluorescent BVR upon excitation at 350 nm. 
Because the hHO-1 absorption spectrum overlaps with the emission spectrum of BVR-
CPM, hHO-1 binding results in fluorescence quenching due to FRET processes. 
Because apoHO has no absorbance in the 350 nm region, this method can only be 
used to evaluate hHO binding. Plotting the % fluorescence quenching at 455 nm versus 
hHO-1 concentration produced a binding curve (Figure 2.19A) that fits to a one-site 
binding model with a Kd of 0.25 ± 0.09 µM, almost identical to the previously reported 
value of 0.22 ± 0.09 µM (27). Similar FRET experiments with hHO-2 and BVR (Figure 
2.19B) provided concentration-dependent, saturable binding curves with a Kd of 0.27 ± 
0.01 µM.  
These results suggest that BVR binds both HO-1 and HO-2 with similar high 
affinity. Equation 5 can be used to estimate a Kd value in situations where the 
concentration of free ligand cannot be estimated due to high affinity and near 
stoichiometric binding. If HO-2 and BVR have a Kd of ~300 nM (as suggested by the 
fluorescence quenching results), Equation 5 predicts 70% of HO-2 should be 
complexed with BVR under the NMR conditions (with 150 µM HO-2 and 150 µM BVR). 
This is clearly inconsistent with the NMR results; therefore, we conducted additional 
experiments to interrogate the source of this apparent discrepancy between the NMR 
and FRET experiments.  
 
EL= 0.5(E0 + L0 + Kd – ((E0 + L0 + Kd)2 – 4E0  L0)1/2)                  [Equation 5] 
 
2.4.11 Fluorescence quenching of BVR-CPM by heme 
 To attempt to resolve the inconsistency between the NMR and fluorescence 
quenching results, we tested the hypothesis that free heme, dissociating from HO-2, 
may be responsible for the fluorescence quenching of BVR-CPM. When free heme was 
titrated into BVR-CPM under conditions identical to those used for hHO titrations, there 
was strong concentration-dependent and saturable quenching of BVR-CPM 
fluorescence (Figure 2.19C), indicating a Kd value of 0.037 ± 0.01 µM. These results 
suggest that the fluorescence quenching observed in the FRET experiments could be 
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due to the effects of heme binding to BVR, or the CPM fluorophore, rather than the HO 
protein. Assuming a Kd of 33 nM for HO-2 and heme (17), Equation 5 predicts that 1 µM 
hHO-2 will contain approximately 0.17 µM dissociated heme, which is well above the Kd 
value determined in these experiments. Thus, we suggest that the quenching of BVR-
CPM fluorescence observed in the titration with hHO-1 or hHO-2 results from free 
heme, dissociated from HO, not the HO protein. We propose that the heme binds to 
BVR-CPM from solution and not through direct heme transfer from the heme-HO 
complex to BVR. In fact, our results demonstrate that these proteins do not form a 
complex, dispelling the possibility of a protein-to-protein heme transfer. 
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Figure 2.19. Fluorescence Quenching of BVR-CPM by Heme Oxygenases and 
Heme. Titration of heme-bound HO-1 (A), HO-2 (B) or heme alone (C) into BVR-CPM.  
Percent fluorescence quenching plotted against the concentration of the titrant and fit to 
a single binding model to determine the Kd of binding using GraphPad Prism 6.0. 
 
The effects of free heme on BVR-CPM fluorescence are consistent with the 
report that heme binds to BVR and to residues 290-296 of the BVR C-terminal peptide 
(KYCCSRK) (36). Furthermore, when we analyzed BVR-CPM by LC MS/MS to 
determine the location of the CPM label, we identified one CPM molecule attached to 
C204 and another to either C292 or C293 of BVR (Figure 2.20). Because C292 and 
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C293 are located on the same peptide in the LC MS/MS analysis, the two cysteines 
were not distinguished by this analysis.  
 
 
Figure 2.20. Biliverdin reductase modified by CPM. LC-MS/MS analysis of BVR-CPM 
identifies CPM modification (*) at C280 and either C292 or C293.  C74 was not 
observed in this analysis. 
 
While the other surface-exposed Cys (C74) is not observed in this analysis, it is 
most likely unmodified because BVR-CPM has enzymatic activity similar to that of the 
wild type protein (109%). We and others (59) find that mutation of C74 in human BVR, 
or its homolog C73 in rat BVR, ablates enzymatic activity. Additionally, CPM labeling 
was conducted in the presence of NADP+, which is expected to protect the enzymatic 
cleft from modification.  
2.4.12 BVR binding heme by optical absorbance 
 To further investigate the possibility that the fluorescence quenching of BVR-
CPM by hHO-2 results from the binding of free heme by BVR, we titrated BVR with free 
heme and measured the absorbance spectrum. As observed by others (36), BVR alone 
shows no optical absorbance in the 350-700 nm range, however in the presence of 
heme, we observe the development of an absorbance band with a wavelength 
maximum at 415 nm, indicating that free heme binds BVR (Figure 2.21A). To determine 
the affinity of heme and BVR, 5 µM heme was titrated with BVR and the absorbance at 
415 nm was measured and fit to a single-site binding model, yielding a Kd of 220 ± 50 
nM (Figure 2.21B).  
Titration of BVR-CPM with hHO-2 produces strong fluorescence quenching; 
however, because there is no evidence of HO-2/BVR binding by NMR, we hypothesize 
that heme, not HO, is responsible for a large part of the fluorescence quenching. To test 
if heme from hHO-2 can bind BVR, we incubated hHO-2 with BVR. Because the 
absorbance of hHO-2 is ~10-fold greater than that of heme-bound BVR and because 
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the absorbance spectra overlap, hHO-2 was included in the reference cuvette for these 
titrations. Under these conditions, with increasing concentrations of BVR titrated into 
hHO-2, absorbance at 415 nm also increases. This result supports that BVR is capable 
of binding heme from hHO-2 (Figure 2.21). 
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Figure 2.21. Heme binds BVR by optical absorbance. (A) The absorbance spectrum 
of 2.5 µM BVR with 2.0 µM heme. BVR alone shows no absorbance in the 350-700 nm 
range. (B) Absorbance at 415 nm for 10 µM heme titrated with varying concentrations of 
BVR (0.05, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.2, 2.0, 3.0, and 5.0 µM BVR). Data are fit to a 
single binding model using GraphPad Prism 6.0. (C) 5 µM hHO-2 alone (dotted line) or 
titrated with various concentrations of BVR (1.0, 2.0, 8.0, 10.0, 20.0 µM). Samples for 
BVR titrations contain 5 µM hHO-2 in the reference cuvette because the absorbance of 
hHO-2 is ~10-fold that of heme BVR and the hHO-2 spectrum overwhelms the heme 
BVR spectrum if it is not subtracted. 
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2.4.13 Chemical cross-linking of HO-2 and BVR 
 The above results suggest that HO-2 and BVR either do not interact or that that 
they form a very weak complex. To determine if an HO-2/BVR complex can be trapped 
by chemical cross-linking, we incubated HO-2, which had been activated with LC-
SPDP, with BVR, as described above for trapping the HO-2/CPR complex. Because 
HO-1 and BVR have been reported to form a complex (24,27), we also conducted the 
experiment with HO-1 as a positive control. Under conditions identical to those used to 
stabilize the HO-2/CPR complex, a high molecular weight complex of ~60 kDa was 
observed by SDS-PAGE for BVR and both HO-1 and HO-2 (Figure 2.16C).  
 Because HO-2 and BVR are similar in molecular mass, a heterodimer of HO-2 
and BVR is not distinguishable from either homodimer by size alone. To determine if 
BVR is directly linked to HO-2 in the cross-linked product, we conducted the cross-
linking reaction using HO-2 that retained an N-terminal 6xhis tag (hisHO-2). The cross-
linked products with hisHO-2 were identical to those with HO-2 by SDS PAGE analysis 
(data not shown). We then isolated hisHO-2 from the cross-linking reaction using Ni-
NTA resin and analyzed the proteins that associated with the affinity resin by reducing 
SDS-PAGE, which was subjected to Western blotting using antibodies against HO-2 or 
BVR. Under these conditions, the cross-linker undergoes reduction, allowing the 
proteins to migrate at their native size. BVR was found to copurify with HO-2 in the 
cross-linked product (Figure 2.16D). A control reaction demonstrated that BVR alone 
did not associate with the affinity resin (Figure 2.16D). These results demonstrate that 
an HO-2/BVR complex can be trapped by chemical cross-linking. 
 To identify the location of the cross-linker in the HO-2/BVR complex, we 
conducted a tryptic digest followed by LC-MS/MS analysis of the cross-linked product. 
This analysis identified the HO-2 peptide containing K264 (KCPFYAAEQKD) linked to 
the BVR peptide containing C292 and C293 of BVR (YCCSR) – the same peptide 
shown earlier to bind heme (36).  
2.5 Discussion 
 In the HO reaction, seven electron-equivalents from NADPH are transferred to 
the HO-bound heme via CPR. For rapid and efficient electron transfer, the electron 
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donor (flavin on CPR) and acceptor (heme of HO-2) should be at optimal orientation 
and distance, implying that an electron-transfer complex is formed during the catalytic 
cycle. One of the issues we have addressed in this paper is the existence and nature of 
that electron transfer complex. One possibility is that HO and CPR form a stable 
complex within which multiple electrons transfer from NADPH through the bound flavins 
(FAD and FMN) on CPR to the HO-bound heme as it undergoes oxygenation and 
conversion to biliverdin and CO. The other possibility is that HO and CPR encounter 
each other only transiently and associate/dissociate multiple times during each catalytic 
cycle. Similarly, either HO and BVR form a stable complex, within which biliverdin is 
transferred (perhaps channeled) between the two proteins, or, as another alternative, 
remain completely unattached as the HO-product (biliverdin) is released into solution 
and captured by BVR to undergo conversion to bilirubin. Based on fluorescence 
quenching, SPR and acetylation-protection studies, a moderately tight HO-1/CPR 
complex with a Kd value in the ~1 µM range had been identified. However, SPR, 
fluorescence quenching, and acetylation protection assays with HO-1 have yielded 
inconsistent results regarding which residues form the HO-1/CPR binding interface 
(24,25,27).  
2.5.1 Interactions between HO and CPR 
 Whether or not HO-2 and CPR form a complex has not been previously 
investigated. As a result of spectroscopic (NMR, fluorescence), steady-state kinetic and 
other biochemical (chromatographic, analytical centrifugation, SPR) studies, we have 
obtained novel information about the nature of the interactions between these two 
proteins.  
 Though our focus is on HO-2, we also analyzed CPR binding to HO-1, primarily 
as a positive control for the HO-2/CPR studies, as CPR binding HO-1 has been 
previously described (24-27). Consistent with previous reports, we observe CPR binding 
HO-1 by SPR and by chemical cross-linking. 
 By gel filtration experiments, under our experimental conditions (50 µM hHO, 50 
µM CPR with NADP+), HO-2 appears to form a homodimer. We do not observe any 
evidence for a complex between HO-2 and CPR. Gel filtration experiments occur under 
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non-equilibrium conditions in which the component proteins of any transient complex, 
once dissociated from the complex, are unable to reassociate once they are in a 
separate zone of the chromatographic column. On the other hand, SPR experiments 
clearly demonstrate CPR binding to HO-2 (Figure 2.14). 
 SPR is a valuable method for studying protein-protein interactions because the 
proteins remain in the same solution and reach equilibrium; furthermore, one can 
monitor both the rates of association and dissociation. Our SPR results clearly 
demonstrate that CPR binds to both HO-1 (Kd of 20.5 µM) and HO-2 (Kd of 16.7 µM) 
with CPR-dependent rates of association and CPR-independent dissociation rates. For 
HO-1, our results give a Kd value that is 10-fold larger than previously reported (24). 
The lower affinity of CPR for HO-1 observed in our studies could be due to differences 
in the experimental design; our studies were conducted in the absence of heme and 
utilized immobilized HO-1 with human CPR as the soluble analyte, whereas earlier 
studies were conducted with immobilized rat CPR with hHO-1 in solution. Although we 
also observe a binding response when we titrate either hHO-1 or hHO-2 against 
immobilized human CPR, we found that free heme also produces a strong ‘binding’ 
response with immobilized human CPR (Figure 2.14E) and with immobilized BVR (not 
shown). Thus, to avoid potential artifacts, these experiments were performed in the 
absence of heme. Our use of the apo-HOs is justified by our NMR experiments, which 
clearly demonstrate that CPR can bind both forms (apoHO-2 and heme-bound) of HO-
2. We are unaware of any physiologic rationale for heme binding to CPR, so this is likely 
to be a nonspecific effect. However, as we discuss below, BVR has previously been 
shown to bind heme and to shuttle heme into the nucleus (36). While by SPR we 
observe no binding of apoHO to immobilized CPR, the conformation of CPR is critical 
for HO-1 binding (26) and it is possible that immobilization of CPR stabilizes a 
conformation that has a lower affinity for HO.  
 Sedimentation velocity experiments also provide evidence of a dynamic complex 
between HO-2 and CPR, with a Kd (15.1 µM) value that is similar to that calculated from 
the SPR data. The HO-2/CPR complex can also be captured by chemically cross-linking 
an amino group of HO-2 through a 15.7 Å tether to a surface-reactive Cys residue on 
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CPR. The latter is, of course, irreversible, and designed to capture even highly transient 
interactions.  
The NMR experiments also show that an interaction between HO-2 and CPR 
occurs. The primary proof is the overall and large loss of peak intensity for the core 
resonances, due to broadening associated with the large increase in time-averaged 
molecular weight. In addition, excess peak intensity loss due to exchange broadening 
and chemical shift perturbations (CSP) occur for several but not all signals. The latter 
observations are compatible with specific binding, and with binding-kinetics that is on 
the fast/intermediate NMR shift time scale (koff ~ 100 s-1). In turn, this is suggestive of a 
Kd in the low µM range, consistent with the values of 15 µM as found by analytical 
ultracentrifugation experiments, and 16.7 µM as found by SPR. Regretfully, the NMR 
experiments do not allow a precise determination of these values, because the NMR 
signals disappear at higher titration stoichiometries and saturation of binding cannot be 
observed.  
 Having assigned ~70% of the resonances in the HO-2 NMR spectrum, we used 
the CSPs to identify the HO-2/CPR interface. Titration of perdeuterated 15N-hHO-2 with 
CPR altered the chemical shift of several residues in the hHO-2 NMR spectrum. At both 
75 and 150 µM CPR, residues of the HO-2 catalytic core exhibit larger CSPs compared 
with the N- and C-termini (Figure 2.4). Residues that exhibit the largest CSPs with the 
addition of 75 µM CPR are F99, Y202, L66, K89, and E190. 
Upon adding CPR, we also observed dramatic and titratable reductions in the 
intensities of some of the 1H-15N TROSY peaks of resonances from the catalytic core 
domain of HO-2 (Figure 2.6 and Figure 2.9). The majority of intensity changes due to 
exchange broadening of the TROSY peaks occur in the structured core region of HO-2, 
with few intensity changes originating from the dynamically unfolded N- or C-termini; 
only Ser8 and Tyr268 exhibit intensity changes in these region. Chemical shift 
perturbations induced by CPR titrations also affect the core residues of hHO-2, while 
the N- and C-termini are unaffected (Figure 2.4). These results indicate that CPR 
interacts with the catalytic core of the protein and has minimal interactions with the N- or 
C-terminal regions of HO-2.  
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 Figure 2.22A highlights residues on hHO-2 that exhibit both significant CSPs and 
large intensity changes with the addition of 75 µM CPR; L66, F99, E102, D193, Q200, 
Y202, and L209. Strikingly, in the recent HO-1/CPR crystal structure, residues of HO-1 
that are conserved with HO-2 residues F99, E102, Q200, and Y202 form a patch that is 
at the CPR interface (Figure 2.22B). The HO-1 residue conserved with D193 is also 
located at the CPR interface, as are HO-1 residues conserved with the HO-2 residues 
identified by mutagenesis, L201 and K169 (Figure 2.22). In the crystal structure, HO-1 is 
bound to a deletion variant of CPR (ΔTGEE) for which the deletion of four residues in 
the hinge region of CPR (residues TGEE) stabilizes an open conformation of CPR 
which has a 10-20-fold higher affinity for HO-1, allowing successful crystallization of the 
HO-1/CPR complex (26). 
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Figure 2.22. The interface for CPR on HO-2 defined by NMR and mutagenesis. (A) 
Residues in red have both significant CSPs and large intensity ratio changes with the 
addition of 75 µM CPR. Residues of HO-2 that are have significant CSPs or large 
changes in peak intensity ratio with the addition of 75 µM CPR are shown in orange. 
The bracket “{“ identifies a patch of residues strongly affected by CPR (F99, E102, 
Q200, L201 and Y202). L201 and K169 were targeted by mutagenesis. Side chains are 
shown as spheres (PDB 2QPP) (B) Residues identified for HO-2 mapped onto the 
analogous residues of HO-1 in the published crystal structure of the complex of rat HO-
1 (grey) and rat CPRΔTGEE (yellow) (PDB 3WKT). Cofactors are as indicated: heme 
(green), NADP+ (blue), FAD (purple), FMN (orange). 
 
 Additional HO-2 residues show either significant CSPs without extra intensity 
change, or large changes in intensity without chemical shift changes. Especially the 
latter phenomenon is prevalent for the most affected residue, L201, and is theoretically 
incompatible with a canonical intermediate exchange binding process as described by 
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Equation 4. Rather, it is suggestive of additional, significantly populated bound states of 
CPR sensed by L201 that are in intermediate/fast exchange with each other and with 
L201 in the free state. It can be shown that the observed broadening without shift can 
occur if the CSP’s of the different bound states approximately cancel (Zuiderweg, 
unpublished). The residues affected by this non-canonical mechanism are conserved in 
HO-1, where they are located at the interface for CPR (E86, D90, E190, L201, R203, 
A208, and D210) or in patches of residues adjacent to the interface in (A31, L33, L36, 
L37, L81, E107, K89, N88, L149, Q172, E182, Thr184, and T215). These residues also 
localize at and around the binding site for HO-2 as identified from CSPs alone. The 
extended nature of the interaction surface would also be compatible with multiple 
binding modes for CPR as implied from the non-canonical broadening. The existence of 
multiple bound states, or an ensemble of encounter complexes, has been suggested for 
other electron-transfer complexes as well {Crowley, 2003 #3581;Ubbink, 2009 #4146}. 
 NMR relaxation and gel filtration studies indicate that HO-2 exists as a 
homodimer in solution at the conditions used. Changes in the homodimerization state of 
HO-2 upon CPR binding could give rise to CPR-dependent changes in the TROSY 
spectrum, and these changes would be difficult to distinguish from changes induced by 
CPR binding HO-2 directly. However, HO-2 crystalizes as a homodimer, and the HO-
2/HO-2 interface is distant from the majority of the CPR induced changes that occur in 
the HO-2 TROSY spectrum (Figure 2.22A). This supports that the CPR-induced 
changes observed in the HO-2 TROSY spectrum are not due to changes in the HO-2 
dimerization state but rather CPR directly binding to HO-2. 
 There is a major difference between the koff as suggested by NMR (~100 s-1) and 
the value measured by SPR (~0.023 s-1). The latter value would give rise to an 
extremely slow NMR shift time scale, and would not allow for any of the observed 
chemical shift changes. This contradictory situation is reminiscent of the binding of an 
organic phosphate molecule to hemoglobin, where, despite an off-rate of 0.01 s-1, fast 
exchange dynamics were observed using 31P NMR. Multiple binding sites for the small 
molecule on the hemoglobin surface were proposed to explain the apparent 
discrepancy and a mathematical model that recapitulated the experimental results was 
described (60,61). In the present case, we have evidence for the existence of multiple 
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bound states of CPR. Perhaps the observed rate of ~100 s-1 as indicated by NMR is 
reflective of the exchange kinetics between the various bound states. In contrast, the 
off-rate as measured by SPR monitors the complete dissociation. 
 While previous reports on the HO-1/CPR complex focus on charge-charge 
interactions (from residues that we were not able to assign in our NMR spectra), our 
results provide the first evidence that hydrophobic residues may be involved in HO/CPR 
binding. The majority of the residues highlighted in the NMR binding studies are 
involved in interacting with the FAD binding domain of CPR (Figure 2.22). Kinetic results 
discussed below concur with these NMR results.  
 Our steady-state kinetic analyses support the conclusion that the area near the 
exposed heme binding face in the catalytic core of HO-2 is involved in binding CPR. For 
example, HO-1 and HO-2, which share a high degree of structural similarity in their 
catalytic core region (55), exhibit similar Km values for CPR (0.5 - 0.7 µM). Furthermore, 
alanine substitution of the core residues that are proposed to be at the HO/CPR 
interface, K169 (or K149 in HO-1) and L201, results in significant increases in the Km for 
CPR. K149A, for example, exhibits a 40-fold increase in Km for CPR, in agreement with 
prior SPR (24) and acetylation protection assays (25), but in contrast with earlier FRET 
measurements, which showed no effect of Ala substitution at that site (27). The K169A 
variant of HO-2 also exhibits a 1.4-fold increase in Vmax and the K149A variant of HO-1 
exhibits a 2.2-fold increase in Vmax suggesting that lowering the affinity for CPR 
increases the steady-state rate under saturating substrate (NADPH, O2, and CPR) 
concentrations. That the K149A variant binds heme with identical affinity as the wild 
type (24) and does not exhibit a decrease (instead a slight increase) in Vmax supports 
our conclusion that its increase in Km for CPR reflects disruption of a key interaction 
between CPR and HO-2, not some major disruption in the overall structure or at the 
active site of HO-1. 
 The HO reaction involves many steps, including heme binding, seven steps of 
electron transfer, three mol of oxygen binding, oxygen activation, biliverdin release, etc. 
It is accepted that the rate-limiting step in the HO-1 catalytic cycle when BVR is present 
is ring opening of Fe(II)-verdoheme (40,62). However, it is possible that this lysine 
variant is rate-limited by another step. The details of the catalytic cycle for HO-2 or for 
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this variant have not been characterized. However, given that K149A (HO-1) and K169A 
(HO-2) exhibit a 1.4-2.2-fold increase in Vmax and a 20-40-fold increase in Km for CPR, it 
seems reasonable to speculate that, at saturating concentrations of CPR, the rate-
limiting step for the lysine variants is electron transfer from CPR to the heme. 
 Taken together, our results suggest that during the multi-step HO-2 reaction, a 
transient complex between HO-2 and CPR forms and dissociates rapidly and that the 
productive electron-transfer complex includes HO-2 residues L201 and K169. The 
transient nature of the interactions between HO-2 and CPR is likely to be an important 
catalytic feature, especially in this and other systems where multiple electrons must be 
passed during each catalytic cycle.  
 Our results indicate that a similar dynamic and transient binding scenario exists 
with HO-1. Our gel filtration and SPR results indicate that HO-1 (like HO-2) forms a 
rather weak complex with CPR. The transient nature of these interactions between HO 
and CPR is likely to be important in the HO mechanism, which requires seven electrons 
to be transferred from NADPH through the redox centers on CPR.  
 The catalytic core, shown clearly to be the domain of HO-2 that interacts with 
CPR, is highly homologous with HO-1. For example, catalytic core residues with NMR 
resonances most strongly affected by CPR that exhibit both CSPs and broadening (L66, 
F99, E102, D193, Q200, Y202, and L209), or with binding constants affected by 
mutagenesis (K169 and L201) are highly conserved between HO-1 and HO-2. All of 
those residues are strictly conserved except L66 (G46 in HO-1). Earlier reports 
identified K149 of HO-1 to be important in binding CPR (24,25). It was shown that CPR 
prevents acetylation of that Lys residue and that substitution of Ala at that position 
results in a 7-fold decrease in affinity for CPR. We found that the K149A substitution 
results in a 40-fold increase in Km for CPR (20-fold for the analogous K169A mutation in 
HO-2). Thus, it appears that both HO’s interact similarly with CPR.  
 Our results support that HO-2 forms a highly dynamic complex with CPR at an 
interface that includes HO-2 residues L201 and K169 and the CPR interface is likely 
highly conserved for both HO-1 and HO-2. As shown in Figure 2.22B, the homologous 
residues in HO-1 (L181 and K149) are located at the HO-1/CPR interface in the crystal 
structure of a complex between HO-1 and a deletion variant of CPR (CPR ΔTGEE) (26). 
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This CPR variant forms a stable complex with HO-1 that, unlike the wild-type protein, 
can be observed even by gel filtration (26). Given the high homology of the structures of 
the catalytic cores of HO-1 and HO-2 (55), we suggest that L201 and K169 of HO-2 
participate in stabilizing the electron transfer complex between HO-2 and CPR. 
2.5.2 Interactions between HO and BVR 
 Based on prior fluorescence quenching studies, HO-1 and BVR were proposed 
to form a high affinity complex (27); and our goal was to characterize the analogous 
HO-2/BVR complex using various biochemical and biophysical methods. However, 
addition of BVR to 15N-labeled hHO-2 results in no chemical shift perturbation and, of 
the 104 assigned resonances in the hHO-2 spectrum, only five exhibit a BVR-
dependent decrease in intensity. Of those residues that exhibit sensitivity to BVR, three 
are on the surface of the crystal structure and could reasonably be involved in binding 
BVR (K176, Q196 and Y229) (Figure 2.18). In contrast, under the same conditions with 
equimolar CPR, 48 of the assigned HO-2 resonances exhibit strong CPR dependent 
effects (Figure 2.9). These results suggest BVR binds hHO-2 with a weak affinity 
compared with CPR.  
 Because the TROSY experiments indicated that HO-2 does not bind BVR with 
high affinity (Figure 2.18), we repeated the original fluorescence quenching studies that 
described the hHO-1/BVR complex (27). Although our results with hHO-1 are nearly 
identical to those described in the original paper, additional controls indicate that free 
heme strongly quenches BVR-CPM fluorescence independently of HO. We also used 
optical absorbance methods to verify the ability of BVR to bind heme, as was reported 
previously (36). The Kd for the heme-BVR complex differs between the two 
experiments, with the absorbance data indicating binding of more than one heme to 
BVR. Furthermore, labeled BVR contains fluorophores at two specific sites (C292 or 
C293 and C204). We suggest that the fluorescence quenching studies may monitor 
binding of one heme to BVR at a high affinity site near one of these fluorophores, while 
the optical absorbance studies may reflect multiple heme binding events.  
 Thus, the fluorescence quenching studies aimed at studying interactions 
between HO-2 and BVR actually derive from binding of heme in solution that has 
 75 
dissociated from hHO, rather than direct interactions between hHO and BVR. In fact, 
detection of an HO/BVR complex requires the use of methods like chemical cross-
linking, where even transient complexes can be trapped. 
 This result describing the low affinity of HO for BVR is important because it 
clarifies the mechanism by which BVR couples to the HO reaction. It has been shown 
that BVR changes the rate limiting step of the HO-1 reaction from biliverdin release to 
the conversion of the Fe2+-verdoheme intermediate to Fe3+-biliverdin (40). We had taken 
this to indicate the possibility that biliverdin is channeled between the two proteins. 
However, it now appears that the effect of BVR on the HO rate limiting step occurs by 
kinetic coupling of the HO and BVR reactions, not substrate channeling. BVR binds HO-
2 very weakly, therefore substrate channeling, which requires a stable complex, is 
unlikely. Thus, BVR simply binds the biliverdin upon release from its product complex 
with HO, enhancing the HO reaction by affecting the mass balance.  
 
2.6 Conclusions 
 In conclusion, we show that protein-protein complexes between HO-2 and other 
proteins in the heme degradation pathway (CPR and BVR) are highly transient. HO-2 
and CPR form a transient electron transfer complex and, like other electron transfer 
pairs, HO-2 and CPR may form an ensemble of complexes that is in equilibrium with the 
productive electron transfer complex. NMR binding studies and mutagenesis of HO-2 
highlight an interface for CPR on HO-2, which is consistent with what has been 
described for CPR and HO-1. However, in contrast to studies with CPR and HO-1, our 
results suggest that CPR binding HO-2 in solution is dynamic. Gel filtration and 
ultracentrifugation studies support a weak/transient CPR/HO-2 complex. Complex 
formation between HO-2 and BVR is undetected, except via irreversible binding (cross-
linking) methods. In the cell, CPR is an electron donor for many biologically important 
reactions. The dynamic interactions between CPR and HO-2 revealed in these studies 
may play an important role in the regulation of the HO system in a cellular context. 
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Chapter 3 An analysis of the role of cysteine residues in biliverdin reductase 
substrate inhibition 
3.1 Abstract 
 Biliverdin reductase (BVR) catalyzes the second step of heme degradation; the 
conversion of biliverdin to bilirubin. Rat BVR possesses three cysteine residues (C73, 
C280, and C291). Reports conflict regarding the requirement of C73 for enzymatic 
activity. Also, BVR is subject to strong substrate inhibition under conditions of high 
biliverdin concentration. Cysteine residues 280 and 291 of rat BVR are implicated in 
substrate (biliverdin) and cofactor (NADPH) binding and may have a role in mediating 
BVR substrate inhibition. In this chapter, the requirement for the cysteines of human 
BVR in catalysis and substrate inhibition are determined by assessing the effect of cys 
to ala substitutions on BVR catalysis and substrate inhibition. Human BVR possesses 5 
cysteine residues with amino acid numbering increased by 1 as compared with rat BVR 
(C74, C204, C281, C292, and C293). Alanine substitution of C74 results in a large 
(~80%) reduction in specific activity, establishing that this residue is important for BVR 
catalysis. The C74A variant is also less sensitive to the addition of biliverdin, indicating 
a relief of substrate inhibition for this variant. Alanine substitution of additional residues 
(C281, C292, C293 and the double substitution C292/C293) does not effect steady 
state catalysis or substrate inhibition, indicating that these residues are not required to 
mediate either aspect of BVR. 
3.2 Introduction to Biliverdin Reductase 
 As described in Chapter 1 of this thesis, the heme degradation pathway consists 
of two enzymatic steps mediated by heme oxygenase (HO) and biliverdin reductase 
(BVR). In the first step, HO converts heme to biliverdin by cleavage of heme at the α-
meso carbon bridge (Figure 1.2) [Equation 1]. The two major isoforms of HO, HO-1 and 
HO-2, share a high degree of homology (55% identity and 76% similarity) and possess 
similar enzymatic activity (1). The HO isoforms HO-1 and HO-2 are 32 and 36 kDa  
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respectively, and both possess a C-terminal membrane spanning region which tethers 
the protein to the cytoplasmic side of the endoplasmic reticulum. The HO isoforms differ 
in their expression and regulation; while HO-1 is transcriptionally regulated and 
expressed in most tissues, HO-2 is expressed constitutively, primarily in the brain and 
testes (2,3) 
 Biliverdin reductase (BVR) mediates the second step of heme degradation, in 
which biliverdin is converted to bilirubin by the reduction of biliverdin at the γ-meso 
bridge (4-6). BVR is a soluble ~33 kDa protein that is predominantly cytosolic. As shown 
in Equation 2, BVR catalysis requires 2 reducing equivalents. BVR is unique in that it 
utilizes reducing equivalents from either NADH or NADPH, and has distinct pH optima 
for the two cofactors (pH ~6.75 for NADH and pH ~8.7 for NADPH) (6,7). NADPH is 
likely the most biologically relevant cofactor as at physiologic pH the Km for NADPH is 
~100-fold lower than the Km for NADH (8). Furthermore, in the cytosol where the 
majority of BVR is located, the NADP+:NADPH couple is predominately reduced, while 
NAD+:NADH is mostly oxidized (9). 
 
 Heme + 7e- + 3O2 → biliverdin + CO + Fe(II) + 3H2O [Equation 1] 
 Biliverdin + 2e- → Bilirubin [Equation 2] 
 
 Because bilirubin is less soluble than biliverdin, and high levels of bilirubin are 
neurotoxic, there has been some question as to why bilirubin is produced (10,11). 
Normal levels of bilirubin, however, are biologically beneficial for a number of reasons 
(12). In some mammals, the reduction of biliverdin to bilirubin facilitates the elimination 
of heme catabolites from the fetus, as the placenta is impermeable to biliverdin but 
permeable to bilirubin (13). In the bloodstream bilirubin is normally bound by albumin to 
enhance its solubility. It is transported to the liver where it is conjugated with glucoronic 
acid to increase solubility and facilitate excretion from the body (14). A balance between 
BR production and excretion is crucial as the accumulation of bilirubin leads to 
hyperbilirubinimia, a common medical complication in newborns that can result in neural 
impairment if not treated promptly (15). Common causes for hyperbilirubinimia are 
excessive bilirubin production, impaired glucuronidation, or acidosis which reduces the 
binding of BR to albumin (16). 
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 While high levels of bilirubin are toxic, low levels confer protection against 
reactive oxygen species (ROS) (17-19). The bilirubin antioxidant system may be 
particularly important in the brain, as low levels of bilirubin (10 nM) protect neuronal 
cells from oxidation by 10,000-fold greater concentrations of hydrogen peroxide (20). 
Also, mice with a deletion of the brain specific HO-2 (HO-2-/-) have reduced bilirubin 
levels and exhibit higher sensitivity to neurologic damage such as cerebral ischemia 
and traumatic brain injury (20,21).  
 In addition to its catalytic activity, additional functions have been ascribed to 
BVR. BVR is a transcriptional regulator of genes involved in the oxidative stress 
response. In vitro studies show that dimeric BVR binds activator protein (AP-1) DNA 
binding sites while monomeric BVR fails to bind DNA (22,23). AP-1 sites are DNA 
binding sites for regulatory proteins containing bzip dimerization motifs (such as BVR, c-
Jun and c-Fos) and are involved in the regulation of oxidative stress responsive genes 
such as HO-1 (24-26). 
 Studies in cells demonstrate a role for BVR in HO-1 transcriptional regulation. 
While under normal conditions BVR is primarily cytosolic, in cells treated with hematin 
BVR translocates to the nucleus and is required for hematin-induced expression of HO-
1 (23,27). Consistent with this observation, BVR is a heme binding protein in vitro (23). 
BVR possesses both nuclear localization and nuclear export signals (NLS and NES) 
and the NLS is required for HO-1 transcriptional activation (23). 
 In addition to its role in transcriptional activation, BVR is involved in a number of 
signaling pathways via its kinase activity. BVR is a rare dual specificity (Ser/Thr and 
Tyr) kinase (28,29) and functions in cell signaling pathways important for regulating 
glucose uptake gene expression. In the insulin signaling pathway, BVR is a target for 
insulin-activated insulin receptor tyrosine kinase (IRK). In cells, a reduction in BVR 
protein levels results in increased uptake of glucose in response to insulin (30). 
Furthermore, exposure of cells to peptides based on the C-terminus of BVR 
(KYCCSRK) modulate glucose uptake and IGF-1 stimulation for those cells (31). BVR 
also plays a role in the mitogen-activated protein kinase (MAPK) signaling pathway, 
which is involved in the transcriptional response to stress (32). BVR possesses MAPK 
binding sites and binds to the MAPK regulators mitogen-activated protein kinase kinase 
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(MEK) and extracellular signal-regulated kinase (ERK) and can activate these 
regulators via its kinase activity. There are many targets for activated ERK, including 
oxidative-stress responsive genes such as HO-1 and inducible nitric oxide synthase 
(iNOS) (32). 
 As described above, BVR and its product bilirubin are involved in various 
processes important for cellular function and health including heme catabolite excretion, 
antioxidant protection, transcriptional regulation, and cellular signaling. Thus, 
understanding the regulatory mechanisms of BVR is important for understanding these 
cellular mechanisms that are important in human health and disease. 
 Early studies characterizing BVR reveal a major mechanism of regulation for the 
enzyme; BVR is strongly substrate inhibited. Also, cysteine residues of BVR are 
implicated in substrate and cofactor binding and may be required for catalytic activity. 
This chapter further addresses the role of cysteine residues in BVR substrate inhibition. 
 BVR undergoes inhibition by thiol-reactive reagents, which inhibit catalytic activity 
for both rat and human BVR, suggesting that cysteine residues play an important role in 
catalytic function (4,8,33). Human BVR possesses five cysteines; C74 is present in the 
enzymatic cleft, C204 is found on the surface of the protein, and C281 is not surface 
exposed, as shown on the BVR crystal structure in Figure 3.1. C292 and C293 are near 
the C-terminus, however the BVR crystal structure contains residues 6-291, therefore 
C292 and C293 are not visible in Figure 3.1. Cysteines C74, C281, and C292 are highly 
conserved across multiple species (Figure 3.2). Rat BVR contains only the three highly 
conserved cysteines, and one fewer amino acid compared with human BVR, resulting in 
slightly differing numbering for the residues (C73, C280 and C291, rat numbering) 
(Figure 3.3). 
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Figure 3.1. Human BVR contains 5 cysteines. The crystal structure of human BVR 
residues 6-291 (PDB 2H63) is shown as a space filled model (top) and as a cartoon 
(bottom). Cysteine side chains are red, while Y291, the most C-terminal BVR residue 
visible, is shown in orange. NADP+ is in green. C292 and C293 are not visible in this 
structure. 
 
 
 
 
 
Figure 3.2. Multiple species alignment of cysteines in BVR. Sequence alignment 
(ClustalW2) of BVR from 12 species focusing on sequence encompassing cysteine 
residues. Numbering corresponds to the human sequence. Gaps represent sequence 
omitted for clarity. 
 
 
 
Human       MNAEPERKFGVVVVGVGRAG SSQEVEVAYICSESSSHEDYI KEDQYMKMTVCLETEKKSPLS LAAEKKRILHCLGLAEEIQKYCCSRK----
Chimp       MNTEPERKFGVVVVGVGRAG SSQEVEVAYICSESSSHEDYI KEDQYMKMTVCLETEKKSPLS LAAEKKRILHCLGLAEEIQKYCCSRK----
Rhesus      MNTEPERKFGVVVVGVGRAG SSQEVEVAYICSESSSHEDYI KEDQYMKMTVCLETEKKSPLS LAAEKKRILHCLGLAEEIQKYCCSRK----
Horse       MNAEPERKFGVVVVGVGRAG SSQEVEVAYICSENSSHEDYI KEDQYMKMTVCLETENKRPLT LAAEKKRILHCLWLAEEIQKHCYSKE----
Dog         MNAEPERKFGVVVVGVGRAG SSQEVEVAYICSESSSHADYI KEDQYMKMTVCLETENKRPLT LAAEKKRILHCLWLAEEIQKYCYSKK----
Cow         MNTEPERKFGVVVVGVGRAG SSQEVEVAFICSESSSHEDYI KEDQYMKMTVCLETENKSPLT LAAEKKRILHCLWLAGEIQKHCCSKQ----
Pig         MDAEPQRRFGVVVVGVGRAG SSQEVEVAFICSESSSHEDYI KEDQYMKMTVCLETENKSPLT LAAEKKRILHCLWLAGEIQKHCCSKK----
Rat         MDAEPKRKFGVVVVGVGRAG RSQEIDVAYICSESSSHEDYI KEDQYMKMTVQLETQNKGLLS LAAEKKRIMHCLGLASDIQKLCHQKK----
Mouse       MSTEPKRKFGVVVVGVGRAG RSQEVDVAYICTESSSHEDYI KEDQYMKMTVQLETQNKSPLS LAAEKKRILHCLELASDIQRLCHRKQ----
Zebrafish   -------MLGSVVVGIGIAG SRDDIHVAFICTENTSHEENI KENKYMKMTAHLLTQQHKPLT LQAERNRILHCLELADRIQQITENTHA---
Chicken     -------MFGTVVVGVGIAG RSKEIHAAFISTENRSHEETI KDKNYSRMTVHFQTANKKPLT LAAEKWRILRCLDLAGMIQQQCEQPEKICS
Xenopus     -------MFGAVVVGIGIAG KSKDIDAAFICTDNQNHEESV KELNYSKLTAHFLTAENRPLT LLAEKQRILKCIDLAEEIKKKCEH------
74 204 281 292/2931
N C
 C74 C204 C281 C292/C293
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B
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Figure 3.3. Cysteines in rat BVR are conserved in human BVR. Human BVR (A) and 
rat BVR (B) are highly conserved with 83.1% identity and 94.9% similarity. Cysteines 
are shown as black bars in their relative locations on the protein. hBVR contains an 
additional amino acid compared to rBVR. 
 
 Additional reports address the role of specific cysteines in rat BVR catalysis by 
determining the effect of cysteine to alanine substitutions at positions C73, C280, and 
C291 (rat BVR numbering). However these studies report conflicting results. One study 
finds the C73A substitution ablates enzymatic activity, suggesting C73 is required for 
catalysis (34). The same study reports the alanine substitution C280A has ~70% 
catalytic activity compared with wild type. However, a second group reports that the 
catalytic activities of both C73A and C280A variants are identical to that of the wild type 
enzyme (35). Thus the requirements for C73 and C280 for BVR catalysis are not clear. 
 Cysteine residues C280 and C291 of rat BVR are proposed to participate in 
substrate (biliverdin) and cofactor (NADPH) binding (34). Alanine substitution for C280 
increases the Km for biliverdin by 3-fold, while the Km for NADPH is unaffected, 
suggesting a role for C280 in biliverdin binding. Substitution of C291 by Ala increases 
the Km for NADPH 4.6-fold, while the Km for biliverdin is unaffected, suggesting that 
C291 plays a role in binding NADPH (34). Both substrate and cofactor binding are 
important for catalysis, as a disruption in either substrate or cofactor binding could result 
in a reduction or loss of catalytic activity. As mentioned above, the C280A substitution 
causes reduced catalytic function (loss of 30% activity), further supporting that this 
residue may be important for BVR activity. While structural perturbations could also 
result in impaired enzymatic function, circular dichroism results demonstrate that the 
structures of the C280A and C291A variants are similar to wild type and that the alanine 
substitutions do not cause large structural changes (34). 
 BVR exhibits substrate inhibition; rat BVR shows dramatic concentration 
dependent inhibition with increasing concentrations of biliverdin (8,36,37). Kinetic 
studies suggest that the formation of the BVR-BV-NADP+ complex is inhibitory and that, 
at high biliverdin concentrations, product release from this complex is the rate limiting 
catalytic step (36). Supporting the existence of a BVR-BV-NADP+ complex, the 
fluorescence of the NADP+ analog etheno-NADP is enhanced in the presence of BVR, 
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but quenched and shifted in the presence of biliverdin, indicating that etheno-NADP and 
biliverdin are in close proximity (36). 
 Because BVR is strongly substrate inhibited and the inhibitory complex is 
reported to be BVR-BV-NADP+, we hypothesize that residues important for substrate or 
cofactor binding are important for mediating BVR:substrate inhibition. To test the 
importance of cysteine residues in human BVR substrate inhibition, we constructed 
alanine substitutions for these cysteine residues and determined the effects on 
substrate inhibition.  
 The analysis described in this Chapter focuses on the highly conserved cysteines 
C74A, C281A, and C292A (hBVR numbering). We determined the effect of Cys-to-Ala 
substitutions on catalytic activity and substrate inhibition. These studies also address 
the conflicting reports regarding the enzymatic requirement for C73 and C280 (or C74 
and C281 in human BVR). In addition to examining the roles of the three highly 
conserved cysteines in hBVR (C74, C281, and C292), we also address the importance 
of C293A, which is not highly conserved but is located adjacent to C292. We find that 
human BVR, like rat BVR, is strongly substrate inhibited. We find little evidence to 
support a major regulatory role for C281, C292 or C293 in human BVR for either 
catalytic activity or substrate inhibition. However, consistent with the previous report by 
Mccourbrey and Maines (1994) we find that C74 of hBVR, equivalent to C73 of rat BVR, 
is important for BVR catalytic activity. 
 
3.3 Materials and methods 
3.3.1 Cloning, expression, and purification of human BVR 
3.3.2 Materials 
Ampicillin, isopropyl-β-D-thiogalactopyranoside (IPTG), NADPH, and bovine serum 
albumin (BSA) were purchased from Sigma (St Louis, MO). OneShot® BL21(DE3) 
chemically competent cells were purchased from Invitrogen/Life Technologies (Grand 
Island, NY). Glutathione Sepharose was purchased from GE Healthcare (Piscataway, 
NJ). Biliverdin (BV) was purchased from Frontier Scientific (Logan, UT). CompleteMini 
EDTA free protease inhibitor tablets were purchased from Roche (Indianapolis, IN). 
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3.3.3 Enzyme purification 
The human BVR gene was purchased from American Type Culture Collection 
(Manassas, VA) and subcloned into the pGEX4T2 plasmid. This vector contains a 
glutathione s-transferase affinity purification tag to facilitate purification of BVR from 
bacterial homogenate. BL21(DE3) cells were transformed with plasmid containing the 
BVR gene, plated on Luria Broth (LB)/Agar with ampicillin (100 μg/ml) and incubated for 
16h at 37°C. 100 mL LB with ampicillin (100 μg/mL) was inoculated with a single colony 
and incubated at 37°C for 16 h with agitation at 250 rpm. For BVR induction, 1 L LB with 
ampicillin (100 μg/mL) was inoculated with 10 mL stationary culture and incubated at 
37°C, 250 rpm until growth reached an OD600 of ~0.8. BVR expression was induced 
with the addition of 300 mM IPTG and cells incubated at 20°C for 16 h, 250 rpm. Cells 
were harvested by centrifugation in a Sorvall© RC5B at 6,000 rpm, 4C for 10 min. Cell 
pellets were frozen in liquid nitrogen and stored at -80°C. 
 Cells were thawed and resuspended in lysis buffer (PBS with 0.5 mg/ml 
lysozyme, 0.4% Triton x-100, 0.5 mg/ml RNase, 2.5 μg/ml DNase, 1 CompleteMini 
EDTA free protease inhibitor tablet (Roche)) by stirring at 4°C for 30 min. Following 
sonication, the homogenate was centrifuged at 30,000 x g for 30 min at 4°C. The 
supernatant was loaded onto 5 mL Glutathione S-Transferase (GST) sepharose and 
washed extensively with 200 mL PBS. BVR was eluted with a linear gradient to 10 mM 
reduced glutathione and the GST purification tag was removed from BVR by limited 
thrombin proteolysis. The affinity tag was then separated from the protein by 
chromatography using glutathione sepharose affinity resin. Purified BVR was snap 
frozen in liquid nitrogen and stored at -80°C. All purification steps were performed at 
4°C. 
3.3.4 Site-directed mutagenesis of hBVR 
Point mutations of hBVR were constructed using the QuickChange site-directed 
mutagenesis protocol (Stratagene, La Jolla, CA). Oligonucleotides were synthesized by 
Integrated DNA Technologies (Coralville, Iowa). Positive transformants were enriched 
by antibiotic selection and confirmed using DNA sequence analysis. All of the variants 
were purified as described above for the wild type enzyme. 
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3.3.5 BVR activity assay  
 BVR activity was assayed as previously described with some modifications (8). 
The assay was conducted in a double beam Shimadzu UV-2600 spectrophotometer at 
20°C. The reaction cuvette contained 0.2 µM BVR, 1 mg/ml bovine serum albumin 
(BSA), 0.5 µM Mg Cl2, 0.1 mM Tris pH 8.0 with varying amounts of biliverdin (BV) in a 
total volume of 1 ml. The reference cuvette contained an identical reaction. The reaction 
was initiated with the addition of 100 µM NADPH. Bilirubin production was monitored by 
the increase in absorbance at A468 and the milimolar difference extinction coefficient 
between bilirubin and biliverdin of 46.0 mM-1 cm-1 was used to determine the specific 
activity of BVR (mM BV/mg BVR/min) (8). 
 
3.4 Experimental results 
3.4.1 The role of cysteines in hBVR steady state enzyme activity 
 To address the requirement for highly conserved Cys residues at positions 74, 
281, and 292 in the catalytic mechanism of hBVR, we replaced each of them with 
alanine and determined the effect on catalytic activity (Figure 3.4). The C74A construct 
is strongly impaired and exhibits only ~20% activity compared with the wild type 
enzyme. This result is consistent with a study with rat BVR that reports a requirement 
for C74 (34). On the other hand, the C281A, C292A, C293A variants had greater than 
95% activity compared with the wild type enzyme, and substitution of both Cys292 and 
293 led to a specific activity that was 78% of that of wild type BVR (Figure 3.4). 
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Figure 3.4. The effect of alanine substitutions of cysteines on BVR activity. 
Specific activity for various BVR constructs monitored by bilirubin production at 468 nm 
(Σ = 46 mM-1 cm-1) for 0.2 µM BVR with 1.5 µM BV as described in methods. Data 
represent the mean of at least three independent experiments and error bars represent 
the standard deviation of the mean. 
 
3.4.2 The role of cysteines in hBVR substrate inhibition 
 Catalytic activity of human BVR is strongly impaired as concentrations of 
biliverdin exceed BVR by 10-fold or more (Figure 3.5). C281A, C292A, C293A, and 
C292A/C293A exhibit similar sensitivity to increasing concentrations of biliverdin, 
suggesting these residues are not required for mediating BVR substrate inhibition. 
C74A is somewhat less sensitive to increasing biliverdin concentrations as compared to 
the other BVR constructs, however catalytic activity for this construct is also 
dramatically impaired (Figure 3.5). 
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Figure 3.5. The effect of alanine substitutions of BVR cysteines on BVR substrate 
inhibition. Specific activity for various BVR mutants with various concentrations of BV 
as described in methods. Activity is expressed as mM BR/mg BVR/min. Bilirubin 
production is monitored at 468 nm (Σ = 60 mM-1 cm-1). (A) Alanine substitutions of BVR 
constructs: wild type, C74A and C281A. (B) Alanine substitutions of BVR constructs: 
wild type, C292A, C293A and C292A/C293A. For clarity, the alanine variants are 
divided into the two groups as described, while WT is shown on both (A) and (B). Data 
represent the mean of at least three independent experiments and error bars represent 
the standard deviation of the mean. 
 
3.5 Discussion 
 Because earlier studies implicate specific cysteine residues in substrate and 
cofactor binding for rat BVR, we tested the conserved Cys residues in human BVR to 
determine their potential role(s) in steady-state catalysis and in mediating substrate 
inhibition. Alanine substitution at C281, C292, or C293 had little effect on hBVR catalytic 
activity (Figure 3.4), in contrast with results obtained with rat BVR (34). On the other 
hand, we find that catalytic activity is strongly impaired for the C74A construct, 
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consistent with a study conducted with rat BVR (34). This result clarifies a requirement 
for an intact cysteine at C74 in hBVR (C73 in rat BVR) that, until now, had been 
controversial.  
 It is not clear why Kikuchi et al observe no loss of catalytic activity for the C73A 
BVR construct as their reported methods are almost identical to those of Mccourbrey et 
al who report impaired activity for the same construct (34,35). One difference in the 
methods is that Kikuchi et al used purified enzyme whereas McCoubrey et al used 
bacterial lysates that were expressing BVR. However in the present study purified BVR 
is used, and we observe a similar loss of activity for the C73A mutant as McCourbrey et 
al, suggesting that the degree of purity for BVR is not a reason for the dissimilar results 
of the two previous studies. 
 The physiologic relevance of substrate inhibition for BVR is not known, however 
substrate inhibition is a regulatory mechanism observed in about 20% of enzymes and 
can be important for regulation of those enzymes (38). Substrate inhibition of BVR could 
regulate enzymatic activity under conditions when cells experience high levels of 
biliverdin levels. For example, after trauma that results in a bruise, the accumulation of 
biliverdin is evident in the greenish color of the bruise (39). Under hemolytic conditions 
such as bruising, large amounts of heme must be degraded due to the breakdown of 
red blood cells. Both HO and BVR require NADPH (HO receives electrons from NADPH 
via cytochrome P450 reductase), and, under conditions where high levels of heme must 
be degraded, competition for NADPH could occur. The Km of BVR for NADPH is ~3 µM 
(8), while the Km of CPR for NADPH is ~5 µM (40). Because free heme is toxic, 
substrate inhibition of BVR could be a mechanism to decrease competition for NADPH 
and favor the HO reaction over the BVR reaction under hemolytic (and perhaps other 
conditions) that result in an accumulation of heme. 
 We observed no major effect on BVR substrate inhibition for the BVR Cys to Ala 
variants C281A, C292A, C293A, and C292A/C293A. These variants all exhibit strong 
substrate inhibition with a very sharp inflection point at ~2 µM BV and at high 
concentrations (~20 µM) of BV exhibit less than 25% catalytic activity. On the other 
hand, the C74A variant does not exhibit a sharp inflection point at high BV 
concentrations, which demonstrates a relief of substrate inhibition for this construct. 
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Catalytic activity is also reduced for the C74A construct, and these results are 
consistent with weak NADP+ binding described for the rat BVR C73A construct (34).  
3.6 Future directions 
 Under the conditions of the present study, C74 of human BVR is important for 
BVR catalytic activity. Studies utilizing rat BVR report alanine substitution of the 
analogous cysteine, C73, is unable to bind an NADP cofactor column, suggesting this 
cysteine is required for cofactor binding (34). The human BVR construct C74A is less 
sensitive to increasing concentrations of biliverdin compared to the other BVR 
constructs, and catalytic activity is reduced.  
 Previous studies suggest a role for C280 and C291 in binding BV and NADPH for 
rat BVR (34). If these residues do indeed play a role in substrate and cofactor binding, 
we would expect that alanine substitution of these residues would affect BVR substrate 
inhibition, which was not the case. Thus the role of C280 and C291 (C281 and C292 for 
human BVR) is unclear. Determining the effect of the alanine substitutions on the 
binding affinity of BVR for biliverdin and NADPH would clarify the role of these residues 
in BVR activity.  
 BVR catalysis does not require C281, C292, or C293 (Figure 3.4) and these 
residues are not required for mediating substrate inhibition (Figure 3.5). Many proteins 
contain cysteines that, under oxidizing conditions, form disulfide bonds which can 
modulate activity of those proteins (41,42). HO-2 posses a redox sensitive dithiol switch 
and the redox state of two C-terminal cysteines affect the affinity of HO-2 for heme (43). 
Given the redox sensitivity of HO-2 in the first step in heme degradation, and the role 
that BVR plays in protection against oxidative stress via production of bilirubin and in 
regulating genes responsible for mediating the oxidative stress response, it’s likely that 
BVR may also be subject to redox regulation. Future studies testing the effects of 
oxidative conditions on BVR activity could help determine if BVR is subject to redox 
regulation. If BVR activity is affected by changes in the redox state, these effects may 
be mediated by the conserved cysteines addressed in the present studies and future 
studies testing requirements for those cysteines may be conducted. 
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Chapter 4 Ongoing Work and Future Directions 
 
4.1 Characterization of the membrane binding HO-2/CPR electron transfer 
complex in vitro 
 Understanding protein-protein interactions between HO and CPR is important for 
understanding regulation of the heme degradation pathway, as electrons transferred via 
CPR are required for the HO reaction. Furthermore, in the cell, the availability of CPR 
could be a limiting factor for HO activity because of it provide electrons for various other 
proteins. In addition to HO, numerous other reactions require electrons via CPR and 
competition for CPR is likely to occur. For example, in mammals multiple cytochromes 
P450 also utilize electrons from CPR, and the ratio of CPR to P450s is ~1:20 (1-3). 
Therefore, the binding of CPR to its respective electron transfer partner is likely a critical 
point of regulation for enzymes that require CPR for catalysis. The first step towards 
understanding the competition among the electron acceptors (e.g. HO and P450s) is 
understanding the binding events that are required to produce a productive electron 
transfer complex. Characterization of the binding interface for soluble HO and CPR in 
vitro increases our understanding of the hydrophobic and electrostatic forces that drive 
the formation of a productive HO/CPR electron transfer complex and this information 
extends to other electron transfer complexes involving CPR. 
 The majority of studies characterizing HO-1 or HO-2 binding CPR have been 
conducted with soluble truncated proteins using a purified cell-free system. Previous 
work by other groups, and work herein, characterize a complex for soluble HO-1 and 
CPR (4-7) and soluble HO-2 and CPR (Chapter 2 of this thesis, Spencer et al., 
manuscript in press). The interface for the HO isoforms and CPR is conserved, with the 
FMN region of CPR binding at an interface on HO-1 or HO-2 that involves K149 or 
K169, respectively, and the FAD domain of CPR binding at an HO interface involving 
L181 or L201 respectively (4-6); (Chapter 2, Spencer et al, manuscript in press). 
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 Recent reports demonstrate that the membrane binding region of HO, and 
possibly the membrane bound environment for both HO and CPR, facilitate complex 
formation between these enzymes (8-11). However, a detailed characterization of the 
electron transfer complex between either full length HO-1 or HO-2 and CPR has not 
been performed and the requirements for the formation of the electron transfer complex 
for the full-length proteins have not been addressed either in vitro or in the cell. 
Therefore, while characterization of the soluble forms of HO and CPR provide valuable 
insight into the mechanisms that could control the HO system in the cell, it is important 
now to address the ability of HO and CPR to form a complex with the fully intact 
proteins that contain membrane anchors, and to understand cellular conditions that may 
promote such interactions. Furthermore, BVR contains a prenylation site and has been 
implicated in membrane binding, so this protein should also be included in studies of 
binary and ternary complexes with full-length HO’s. 
 In Appendix 1 of this thesis, I have described a bifluorescence recombination 
(BiFC) system to address protein-protein interactions for HO-2 in a cellular context. HO-
2 and BVR can form a fluorescent BiFC complex in mammalian cells, demonstrating 
that this method will be valuable in interrogating HO-2/CPR binding for full-length 
proteins in the cell. Future experiments in which the BiFC system is used to measure 
complex formation between full-length HO-2 and CPR could be valuable avenues to 
examine this binary complex within a cellular context. Specific residues of HO-2 are 
clearly implicated in binding CPR; L201 and K169 of HO-2 are important for the 
formation of a productive HO-2/CPR electron transfer complex for the soluble proteins 
in vitro (Chapter 2 of this thesis, Spencer et al. in press). Targeted mutagenesis studies 
using HO-2 and CPR BiFC constructs could determine the requirement of these 
residues for complex formation for the full-length proteins, in the context of the cell.  
 Understanding cellular conditions that may affect HO-2 catalytic activity is 
important as HO-2 is constitutively expressed and mechanisms for regulating its 
catalytic activity are not fully understood. Oxidative stress is likely to affect HO-2 
catalytic activity in the cell. HO-2 possesses Cys-Pro heme regulatory motifs (HRMs) 
that modulate the enzyme’s ability to bind heme. The disulfide state of the two C-
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terminal HRMs is sensitive to the redox state of the cell, and under oxidizing conditions 
the affinity of HO-2 for heme is increased ~10-fold (12,13). Additionally, the end product 
of the heme oxygenase pathway, bilirubin, protects the cell against oxidative challenge 
(14-16).  
 Because oxidizing conditions affect the affinity of HO-2 for heme and increase 
the need for antioxidant bilirubin, I expect that oxidizing conditions would modulate the 
activity of HO-2 in the cell. Access to CPR is likely limiting for HO activity, and therefore 
I hypothesize that oxidative conditions would also increase protein-protein interactions 
for HO-2 and CPR. This hypothesis can be tested by determining the effects of the 
cellular redox state on the HO-2/CPR complex using an HO/CPR BiFC system, similar 
to what I have described for HO-2/BVR in Appendix 1.  
 Changes in heme levels in the cell may also result in altered activity of HO-2; 
increased HO activity would protect the cell from the cytotoxic effects of high heme 
concentrations (17). If CPR binding is a limiting factor for HO-2 activity in the cell, high 
heme levels would be expected to increase HO/CPR binding. Again, a BiFC system 
using HO and CPR can address the ability of intracellular heme levels to affect HO-
2/CPR binding. 
 In conclusion, I have characterized the binding of soluble HO-2 with soluble CPR, 
which represents an important regulatory step in the HO pathway. Future studies to 
characterize these interactions with full-length proteins in the context of the cell will 
provide valuable insight into the nature of the full length HO/CPR electron transfer 
complex and how the heme degradation system responds to various cellular conditions 
such as oxidative stress or high levels of heme. 
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Appendix 1 An analysis of HO-2/BVR protein-protein interactions in cells 
A.1 Abstract 
 Heme oxygenase (HO) and biliverdin reductase mediate the first and second 
steps of heme degradation, respectively. HO exists as two major isoforms, HO-1 and 
HO-2. Other groups have previously described a complex between a soluble form of 
HO-1 (residues 1-265) and BVR using a variety of in vitro methods, however the ability 
of HO-2 and BVR to form a complex has not been addressed. Here we describe a 
bifluorescence recombination (BiFC) method to evaluate the ability of full length HO-2 to 
form a complex with other proteins in a cellular context. A split fluorophore with one half 
fused to the N-terminus of HO-2 and the complimentary half fused to the C-terminus of 
BVR is able to recombine to produce fluorescence when the complimentary BiFC 
constructs are coexpressed in mammalian cells. The membrane spanning region of HO-
2 is not required for fluorescence reassembly, however the subcellular localization of 
the BiFC complex is determined by the subcellular localization of HO-2. Full length HO-
2 is tethered to the endoplasmic reticulum while HO-2 that lacks the membrane-
spanning region is cytosolic. The subcellular localization of the HO-2/BVR BiFC 
complex reflects the predicted subcellular localization of soluble and full length HO-2.  
 Chemical cross linking stabilizes an HO-2/BVR complex via the C-terminal 
cysteines of BVR (either C292 or C293). To determine if these cysteines are required 
for formation of the BiFC complex, BVR variants with serine substitutions at C292 or 
C293 were tested for their ability to form a BiFC complex with HO-2. BiFC complexes 
are observed for HO-2 and the BVR variants, indicating that the C-terminal cysteines of 
BVR are not required for the formation of the HO-2/BVR BiFC complex.  
 103 
A.2 Introduction to Heme Oxygenase and Biliverdin Reductase 
A.2.1 Protein-protein interactions between soluble HO and CPR or BVR 
 Full-length heme oxygenase (HO) contains a C-terminal membrane-spanning 
region that, in the cell, tethers the protein to the endoplasmic reticulum. The majority of 
in vitro studies involving HO have been conducted using the truncated forms of HO-1 
and HO-2 in which the membrane anchor has been removed, using protein that was 
exogenously expressed and purified from E. coli. These forms of HO are more soluble 
and stable than the full length protein (1). The truncated versions of the proteins, HO-
1(tn) and HO-2(tn), are comprised of residues 1-265 and 1-288, respectively. Full length 
cytochrome p450 reductase (CPR) possesses an N-terminal membrane spanning 
region that also tethers the reductase to the ER, however in vitro reports addressing 
soluble HO typically also use a soluble form of CPR (amino acid residues 66-680). 
 Protein-protein interactions between HO-1(tn) and the other enzymes involved in 
heme catalysis, CPR and biliverdin reductase (BVR), have been reported, primarily 
using in vitro studies in cell free systems with purified proteins. Surface plasmon 
resonance and fluorescence quenching studies report Kd values ranging from 0.4-2.0 
µM for HO-1 and CPR, while an acetylation protection assay and SPR studies identify 
lysine residue 149 of HO-1 as important for binding CPR (2-4). Additionally, a recent 
crystal structure of a complex of HO-1(tn) with a CPR variant (ΔTGEE) has been 
reported (5). We find that an alanine substitution of K149 increases the Km of CPR for 
HO-1(tn) by ~40-fold, consistent with a role for this residue in CPR binding HO-1 
(Chapter 2 of this thesis, Spencer et al. manuscript in press). 
 Similar studies support that HO-1 and BVR may form a complex. Fluorescence 
quenching studies report Kd values ~0.2 µM for HO-1 and BVR (4). SPR studies 
indicate that BVR can compete with HO-1 for binding to immobilized CPR (2). Finally, in 
the presence of BVR, the rate limiting step for the HO-2 reaction is altered from 
biliverdin release to the conversion of Fe2+-verdoheme to Fe3+-biliverdin (6). However, in 
chemical modification studies in which HO-1 was subjected to acetylation, while the 
addition of CPR protected specific residues of HO-1 from chemical modification, no 
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protection from acetylation was observed upon addition of BVR (3). This suggests that, 
in contrast to CPR, BVR and HO-1 may not form a stable complex. 
 While complexes for HO-1 and CPR, and to a lesser extent HO-1 and BVR, have 
been described, little is known about the ability of HO-2 to form a complex with either 
CPR or BVR. 
A.2.2 A role for the HO membrane spanning region in protein-protein interactions 
 While the majority of studies with HO have been performed with the truncated, 
soluble form, some recent reports suggest that the membrane-spanning region of HO 
enhances its interactions with CPR. A Km value of 0.01 µM for CPR is reported for full 
length HO-1, (7) while we observe a Km value 0.5 µM for the soluble proteins (Chapter 2 
of this thesis, Spencer et al. manuscript in press). This value is ~50-fold lower than the 
Km for CPR with the truncated form of HO-1, suggesting that the full length proteins bind 
more tightly than their soluble counterparts. Additionally, co-purification studies with 
both HO-1 and HO-2 demonstrate that CPR copurifies more efficiently with the full 
length HOs compared with the soluble forms (8). 
 Our results in Chapter 2 of this thesis indicate that BVR and the truncated soluble 
form of HO-2 do not form a high affinity complex. While the membrane-spanning 
regions or the membrane environment appears to facilitate HO/CPR interactions, the 
requirements of the HO transmembrane region has not been addressed for its 
interactions with BVR. 
A.2.3 Fluorescence recombination to characterize protein-protein interactions in 
live cells 
 While a complex for soluble HO-1 and BVR has been described , less is known 
regarding the ability of HO-2 and BVR to form a complex. Because the membrane-
spanning region has been to shown to facilitate protein-protein interactions, here we 
address the ability of full length HO-2 to form a complex with BVR in the physiologic 
context of the cell. 
 Green fluorescent protein fragment reassembly (GFPR) and bimolecular 
fluorescence complementation (BiFC) are methods in which non-fluorescent halves of a 
split fluorophore are fused to putative protein binding partners. Binding of the proteins of 
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interest brings the non-fluorescent fluorophore halves into close proximity permitting the 
reassembly of a fluorescent molecule (9-11). Thus protein-protein interactions can be 
monitored directly by fluorescence. These methods allow protein-protein interactions to 
be examined using proteins in their native cellular environment, an ideal scenario for 
membrane-bound proteins such as HO. Furthermore, the refolding of the fluorophore is 
essentially irreversible which can facilitate the detection of weak or transient interactions 
(9). 
 To address the ability of HO-2 and BVR to form a complex in the cell, 
fluorescence reassembly methods were therefore employed. The fluorescence 
recombination system described here can also be used to interrogate the ability of HO-2 
to bind other proteins in the HO pathway such as CPR, and to define requirements for 
those interactions.  
 
A.3 Materials and methods 
A.3.1 Construction of chimeras for GFPR analysis of HO-2 and BVR 
 The HO-2 cDNA sequence encoding the full length protein (amino acid residues 
1-316) was inserted into the GFPR expression vector pET11a-link-NGFP using 
polymerase chain reaction (PCR) amplification with 3’ primers that introduced a XhoI 
site and 5’ primers that introduced a BamHI site using PFU polymerase (Agilent; Santa 
Clara CA). The PCR product was then inserted into the ZeroBlunt TOPO vector 
according to the manufacturers instructions (Invitrogen/Thermo Fisher Scientific; Grand 
Island NY). Both HO-2 insert (from the TOPO subcloning vector) and vector (pET11a-
link-NGFP) were subjected to restriction enzyme digestion with XhoI and BamHI and 
the subsequent insert or vector purified from 1% agarose gel using the QIAquick gel 
extraction kit according to the manufacturers instructions (Qiagen; Valencia CA). The 
HO-2 insert was ligated into the pET11a-link-NGFP vector using T4 DNA ligase 
according to the manufacturer’s instructions (Promega; Madison WI). Ligation products 
were transformed into Top10 cells (Invitrogen/Thermo Fisher Scientific; Grand Island 
NY ) and plated on Luria broth/agar plates with appropriate antibiotic selection (50 µg/ml 
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kanamycin). DNA constructs were screened using restriction digestion and the 
sequence confirmed by DNA sequencing. 
 The BVR cDNA sequence encoding residues 1-296 was inserted in frame into 
the GFPR expression vector pMRBAD-link-CGFP using the method described above, 
with restriction enzyme sites NcoI and AatII (3’ and 5’, respectively) using ampicillin 
selection (100 µg/ml).  
 GFPR expression vectors and positive controls (NZ and CZ) were a kind gift from 
Dr. Lynne Regan (Yale University, New Haven, CT). 
A.3.2 Expression and visualization of GFPR by microscopy 
 The indicated GFPR constructs were transformed into BL21(DE3) cells according 
to the manufacturers protocol (Thermo Fisher Scientific; Grand Island NY) and cultured 
for 16 h at 37°C on Luria broth agar plates with the appropriate antibiotic selection: 
kanamycin (50 µg/mL) for pET11a-link-NGFP based constructs and ampicillin (100 
µg/mL) for pMRBAD-link-CGFP based constructs. Individual colonies were used to 
inoculate 5 mL 2xYT (2 x yeast extract and tryptone) broth with the appropriate 
antibiotic resistance and cultures were incubated for 16 h at 37°C, 250 rpm. Protein 
expression was induced with 10 µM IPTG for pET11a-link-NGFP based constructs and 
0.2% arabinose for pMRBAD-link-CGFP based constructs for 16 h at 20°C, 250 rpm. 
 To visualize fluorescence, 100 µl of the bacterial culture was concentrated by 
centrifugation at 5 x g for 2 min at 4°C and resuspended in 50 µl 1xPBS. 5 µl of 
concentrated bacterial culture was applied to a poly-l-lysine coated coverslip (BD 
Biosciences, San Jose, CA) and mounted to a slide with 5 µl prolong gold (Thermo 
Fisher Scientific; Grand Island NY). 
 Fluorescence images were acquired on an Olympus BX60 upright microscope 
(Olympus; Center Valley PA) in the Center for Live Cell Imaging at the University of 
Michigan Medical School. Illumination was provided from a 100 W halogen lamp for 
bright-field microscopy and by a BH@-RFL-T# 100W high pressure mercury lamp 
burner for fluorescent microscopy. Images were collected using a 100 x UPlanApo (oil-
immersion) objective with a U-MWB2 filter for GFP fluorescence (Ex460-490 nm, 
Em520 nm). An Olympus DP70 CCD color camera (Olympus; Center Valley PA) using 
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DP70 controller/manager software v3.03 col was used to capture images. Identical 
conditions were used to collect images unless otherwise specified.  
A.3.3 Construction of chimeras for BiFC analysis of HO-2 and BVR 
 The BiFC plasmids pBiFC-VN173, pBiFC-VC155 and pBiFC-CC155 were 
generously provided by Dr.Chang-Deng Hu (Purdue University, West Lafayette, IN) 
(10). These constructs encode amino acid residues 1-173 of Venus (VN173), residues 
155-238 of Venus (VC155) and 155-238 of enhanced cyan fluorescent protein (CC155). 
Residues 155-238 of VC and CC are identical except for 2 amino acid changes - 
residues 145 and 146 are TA and AC for Venus and eCPF respectively. The 
fluorescence emission of the reassembled fluorophore is primarily determined by the 
nature of the N-terminal fragment, and reassembly of VN173 with either VC155 or 
CC155 produces fluorescent proteins with similar spectral characteristics (12,13). 
 To produce a soluble HO-2 BiFC construct, HO-2(tn), the HO-2 sequence lacking 
the C-terminal membrane spanning region (residues 1-288) was amplified by 
polymerase chain reaction (PCR) using a 5’ primer pair that introduced a SalI site and a 
3’ primer pair which generated a BglII site with PFU polymerase (Agilent; Santa Clara 
CA). The PCR product was then inserted into the ZeroBlunt TOPO vector according to 
the manufacturers instructions (Invitrogen/Thermo Fisher Scientific; Grand Island NY). 
Both the HO-2(1-288) insert (from the TOPO subcloning vector) and vector (pBiFC-
VC155) were subjected to restriction enzyme digest with SalI and BglII and the 
subsequent insert or vector was purified from a 1% agarose gel using the QIAquick gel 
extraction kit according to the manufacturers instructions (Qiagen; Valencia CA). The 
HO-2(1-288) insert was ligated into the pBiFC-VC155 vector using T4 DNA ligase 
according to the manufacturer-provided protocol (Promega; Madison WI). Ligation 
products were transformed into Top10 cells (Invitrogen/Thermo Fisher Scientific; Grand 
Island NY) and plated on Luria broth/agar plates with the appropriate antibiotic 
selection. DNA constructs were screened using restriction digestion and the sequence 
confirmed by DNA sequencing. 
 BVR was inserted into the pBiFC-VN173 and pBiFC-CC155 vectors following 
similar methods as described for HO-2 using BglII and XbaI restriction sites (5’ and 3’ 
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respectively) for pBiFC-VN173 and a SalI and BglII (5’ and 3’ respectively) for pBiFC-
CC155. 
 To generate the full length HO-2 BiFC construct, HO-2(FL), residues 1-316 of 
HO-2 were inserted into the pBiFC-VN(1-173) vector according to the methods 
described above, using the restriction sites BglII and XbaI (5’ and 3’ respectively). The 
subsequent fusion protein results in the fluorophore fused to C-terminus of HO-2. 
Because full-length HO-2 is anchored to the ER with the catalytic core facing the cytosol 
and the C-terminus facing the ER lumen, this C-terminus fusion is therefore expected to 
be present in the ER lumen and not available to recombine with a cytosolic protein such 
as BVR. Therefore, another chimera was generated with the fluorophore fragment fused 
to the N-terminus of full length HO-2.  
 To generate the N-terminal VN(1-173) fluorophore, the full length HO-2 BiFC 
construct with a C-terminal fusion was modified as follows. The VN(1-173) sequence 
was PCR amplified with 5’ and 3’ primers containing compatible restriction sites (EcoRI 
and BglII, respectively) to insert the VN(1-173) sequence upstream of HO-2. The PCR 
product was subcloned into the TOPO vector, and insert and vector were prepared and 
ligated as described above. Then, to remove the fluorophore fused to the C-terminus of 
HO-2(FL), a stop codon was introduced after amino acid residue 316 of HO-2 using the 
QuickChange site directed mutagenesis protocol (Strategene; La Jolla CA). The 
resulting full length HO-2 fusion protein with the N-terminal fluorophore exhibited a 
molecular mass of ~44 kDa as determined by SDS-PAGE and Western blot analysis, 
consistent with the size of HO-2 and the VN1-173 fluorophore, confirming that the 
insertion of a stop codon was effective in eliminating expression of the C-terminal 
fluorophore. 
 To generate the BVR(C292S) and BVR(C293S) pBiFC-CC155 variants of BVR, 
site directed mutagenesis was conducted according to the QuickChange protocol 
(Stragegene; La Jolla CA). 
 DNA sequencing was used to confirm the sequence of all DNA constructs 
described.  
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A.3.4 Expression and visualization of BiFC by microscopy 
 HEK293 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM; 
Gibco/Thermo Fisher Scientific; Grand Island NY) supplemented with 10% fetal bovine 
serum (FBS) and 2 mM L Glutamine at 37°C, 5% CO2. Cells were transfected with 0.25 
µg/mL of the indicated BiFC construct(s) using Lipofectamine2000 according to the 
manufacturer’s protocol (Thermo Fisher Scientific; Grand Island NY). Briefly, cells were 
plated on poly-l-lysine coated glass bottom slides (Lab-Tek; Hatfield PA) 24 hours 
before transfection at a density of 500,000 cells/ml. Under these conditions cells were 
~60% confluent at the time of transfection. Cells were then incubated for 24 hours post-
transfection before visualization of BiFC. Immediately before BiFC visualization cells 
were incubated 1µM ER tracker and 5 µg/mL Hoechst for 20 min at 37°C, 5% CO2. 
Cells were then washed with HBSS (Hanks Balance Salt Solution; GIBCO/Thermo 
Fisher Scientific; Grand Island NY) and visualized. 
 BiFC images were collected from live cells using a heated stage (Harvard 
Apparatus, Incl; Holliston MA) and an Olympus IX70 inverted microscope (Olympus; 
Center Valley PA) in the Center for Live Cell Imaging (CLCI) at the University of 
Michigan Medical School. Fluorescent microscopy images were illuminated with an X-
Cite 120 metal halide light source (EXFP; Mississauga, OM, Canada) using a 100 x oil 
immersion objective. Filters used for the various fluorophores were: Venus: excitation 
492 nm/BP18 and emission 535 nm/BP40; ER tracker: excitation 572 nm/BP23 and 
emission 630 nm/BP60; Hoechst: excitation 350 nm/BP50 and emission 465 nm/BP30.  
 Images were collected using a CoolSNAP HQ2 14-bit CCD camera 
(Photometrics; Tucson AZ). All devices were controlled through Metamorph Premier 
v6.3 software (Molecular Devices; Downington PA).  
 For colocalization studies, cells were prepared as described above and imaged 
using a TILL iMIC widefield inverted microscope (TILL Photonics; Graefelfing; Bavaria 
Germany) with a fully automated motorized travel stage and Z-axis control using a Plan 
Super Apochromat 100x oil immersion objective. Illumination for fluorescence images 
was provided by a Till Oligochrome 150W Xenon source (TILL Photonics; Graefelfing; 
Bavaria Germany). Images were acquired using an Andor iXO DU897 cooled EMCCD 
camera. Image acquisition was controlled by Till LA software (TILL Photonics; 
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Graefelfing; Bavaria Germany) and image processing and deconvolution of z-stacks 
was conducted using Imaris (Bitplane; South Windsor CT). Colocalization of the 
deconvoluted images was evaluated by determining the Pierce coefficient using JACoP 
(ImageJ) according to published methods (14). 
A.3.5 Analysis of BiFC by flow cytometry 
 For flow cytometry, HEK293 cells were plated on 12 well flat bottom tissue 
culture plates (Corning® Costar®, Corning NY) and transfected with the indicated BiFC 
constructs as described for BiFC visualization by microscopy. Cells were prepared 
according to published methods (13). Briefly, cells were washed with PBS and lifted 
from the plate by incubation with 0.15 M KCl and 0.015 M Na-citrate in PBS for 5 min at 
37°C, 5% CO2. Cells were then collected, washed with PBS, and suspended in 250 µl 
0.8% BSA in PBS. Flow cytometry analysis was conducted using a FACS Aria II cell 
sorting system (BDBiosciences; San Jose CA) at the University of Michigan Flow 
Cytometry Core in the Office of Research. 
 Analysis was restricted to live cells by gating cells that exhibited forward and 
side-scatter features typical of live cells. To analyze fluorescence events of transfected 
cells, threshold values were set for BiFC that excluded 99% of non-transfected cells and 
the fluorescence events were determined for 10,000 cells. Histogram and error bars 
represent the mean and standard deviation from 3 independent experiments. 
A.3.6 Chemical cross-linking of HO and BVR or RNase 
The reducible, heterobifunctional cross-linker (succinimidyl 6-(3-[2-pyridyldithio]-
propionamido)hexanoate) (LC-SPDP) was used in a two-step reaction according to the 
manufacturer’s instructions (Thermo Scientific/Pierce, Rockford, IL). HO-1 or HO-2 was 
activated as follows: a fresh 3 mM solution of LC-SPDP was prepared in DMSO. 10 µM 
HO-1 or HO-2 was prepared in conjugation buffer (0.1 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), pH 7.5, 30 mM ethylenediaminetetraacetic acid 
(EDTA), 150 mM NaCl) and incubated with 0.1 mM LC-SPDP for 30 min at room 
temperature. Unconjugated cross-linker was then removed by 3 rounds of buffer 
exchange using 10,000 MWCO Amicon microconcentrators (Millipore, Billerica, MA). 10 
µM BVR, or RNase was then added to the activated protein and the reaction was 
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incubated at 4°C overnight. Cross-linking reactions were analyzed by 5-15% gradient 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) (BioRad, 
Berkeley, CA) and visualized by staining the gel with Coomassie blue (15).  
A.3.7 Co-purification of BVR with HO-2 
For the co-purification of BVR with HO-2, the cross-linking reaction was performed 
exactly as described above, however HO-2 contained an N-terminal 6xHis tag (hisHO-
2) that was absent in the other reactions. By SDS-PAGE, the cross-linked products of 
the reaction containing hisHO-2 and BVR migrated to identical positions as those in 
which the 6xHis tag had been removed from HO-2. Samples of hisHO-2 alone, BVR 
alone, or cross-linked hisHO-2/BVR were incubated with 100 µl of Ni NTA resin (50% 
slurry) for 2 hours at 4°C. Samples were rotated on a Boekel variable speed mini-tube 
rotator (Fisher Scientific; Pittsburgh PA). Affinity resin and associated proteins were 
harvested by centrifugation for 5 minutes at a setting of 2,400 x g at 4°C with an 
accuSpin Micro 17R refrigerated microcentrifuge (Fisher Scientific; Pittsburgh PA) and 
washed three times with 1 ml of wash buffer (50 mM Tris-HCl pH 8.0, 30 mM NaCl, 20 
mM imidazole). Protein bound to the resin was eluted with 50 mM Tris-HCl, pH 8.0, 30 
mM NaCl, 300 mM imidazole. Eluted fractions were boiled for 5 minutes in SDS-PAGE 
loading buffer (50 mM Tris-HCL, pH 6.8, 2% (w/v) SDS, 0.1% (w/v) bromophenol blue, 
10% (v/v) glycerol, and 100 mM dithiothreitol) and separated by 10% SDS PAGE (15). 
Proteins were then transferred to a nitrocellulose membrane and detected using 
antibodies against either HO-2 (16) or BVR (Abcam, Cambridge, MA). 
 
A.4 Experimental Results 
A.4.1 A green fluorescent protein reassembly (GFPR) system for assessing 
protein-protein interactions between HO-2 and BVR 
 While protein-protein interactions have been described for HO-1 and BVR, the 
majority of these experiments were performed in vitro using the soluble form of HO-1 in 
a purified system (2-5). The ability of HO-2 and BVR to form a complex has not been 
addressed. While valuable information can be obtained from a purified system, more 
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recent data indicates that the HO-1 membrane-spanning region facilitates protein-
protein interactions (7,8,17). The goal of our experiments is to address the ability of HO-
2 and BVR to form a complex in the cellular context using full length HO-2.  
 Green fluorescent protein reassembly (GFPR), in which non-fluorescent halves 
of GFP are fused to the protein binding partners of interest, permits the direct detection 
of binding interactions via fluorescence (9,18,19). Binding of the GFPR fusion proteins 
brings the non-fluorescent GFP halves into close proximity, permitting the GFP 
fragments to reassemble into a fluorescent protein. Reassembled GFP has spectral 
properties identical to those of intact GFP (19). When the GFP halves are not fused to 
proteins that form a complex, the GFP halves fail to produce a reassembled fluorescent 
protein (19). In addition to permitting the analysis of protein-protein interactions in the 
more native context of a cell, GFPR can enhance the detection of weak/transient 
interactions by stabilizing or trapping the complex of interest. Protein complexes with Kd 
values ranging from 1 μM to 1 mM have been successfully detected using GFPR 
methods (9). 
 The GFPR protein constructs described here consist of a GFP molecule split into 
N- and C-terminal fragments between residues 157 and 158. The non-fluorescent GFP 
halves are fused to the N-terminus of HO-2 or C-terminus of BVR (Figure A.1). While 
the individual GFP halves are not fluorescent, the binding of BVR to HO-2 could bring 
their respective GFP fragments into close proximity, allowing the reassembly of a 
productive fluorescent molecule. Thus, HO-2/BVR binding can be directly monitored via 
fluorescence. As a positive control, GFPR constructs fused to leucine zipper motifs for 
which protein-protein interactions have been well characterized, are also used (19).  
 
 
BVR cGFP
Spacer
N C
A
B
nGFP HO-2
Spacer(His)6 tag
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Figure A.1. GFPR fusion proteins for HO-2 and BVR. (A) Full length HO-2(1-316) was 
cloned into the GFPR expression vector pET11a-link-NGFP to produce a protein 
construct with an N-terminally fused GFP fragment as shown. The hatched rectangle 
represents the HO-2 membrane spanning domain. (B) BVR was cloned into the GFPR 
expression vector pMRBAD-link-CGFP to produce a protein construct with a C-
terminally fused GFP fragment as shown. 
 
 To interrogate the ability of HO-2 and BVR to form a GFPR complex, BL21(DE3) 
cells were co-transformed with the indicated GFPR constructs and fusion protein 
expression was induced as described in the Methods section. The co-expression of HO-
2 and BVR GFPR constructs, or the compatible leucine zipper fusion constructs, 
produces E. coli cell that exhibit green fluorescence, while transformation of cells with 
the individual GFPR constructs resulted in no detectable fluorescence (Figure A.2). The 
leucine zipper constructs NZ and CZ are reported to have high affinity and robust GFP 
reassembly and were used as a positive control (9,19). These results indicate that full 
length HO-2 and BVR are capable of forming a complex in cells and that the orientation 
of the GFP fragments fused to HO-2 and BVR is correct to permit visualization of HO-
2/BVR binding. 
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Figure A.2. Coexpression of HO-2 and BVR GFPR constructs produces 
fluorescence. (A) E.coli cells transformed with HO-2/BVR GFPR constructs are 
fluorescent. Cells transformed with only HO-2 (B) or BVR (C) GFPR constructs lack 
fluorescence. (D) Cells transformed with GFPR positive control constructs (NZ/CZ) also 
produce fluorescence. Exposure time is indicated in the lower right corner of the image. 
 
A.4.2 A bifluorescent recombination system for interrogating HO-2 and BVR 
interactions in mammalian cell 
 While the GFPR results show that HO-2 and BVR can form a complex, similar to 
that described for HO-1 and BVR, the cellular context and architecture of a bacterium is 
quite distinct from that of a mammalian cell. While in the mammalian cell HO-2 is 
tethered to the endoplasmic reticulum, there is no analogous membrane in E. coli. To 
address the ability of HO-2 and BVR to form a complex in the more physiologic 
exp: 1/2.0 s
exp: 1/2 s
exp: 1/2.0 s
exp: 1/2.0 s
exp: 1/2.0 s exp: 1/2.0 s
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mammalian cell, a bifluorescent recombination (BiFC) approach was utilized. Like 
GFPR, BiFC utilizes the reassembly of a split fluorophore fused to putative protein 
binding partners. While the fluorophore fragments individually exhibit no fluorescence, 
protein-protein binding of a BiFC pair can bring the fluorophore fragments into close 
proximity allowing reassembly of a fluorescent molecule. Similar to GFPR, protein-
protein interactions can be monitored via fluorescence and the reassembled fluorophore 
can stabilize transient protein-protein interactions. However, the BiFC constructs are 
mammalian expression vectors and therefore protein-protein interactions can be 
interrogated in the more physiologic context of the mammalian cell. 
 HO-2, lacking the C-terminal membrane spanning region (residues 1-288) and 
full length HO-2 (residues 1-316) were inserted into the BiFC fusion vectors and BVR 
was inserted into expression vectors for the cognate half of the split fluorophore as 
described in the Methods (Figure A.3). C-terminal fluorophore fragments are derived 
from either Venus and eCFP, however residues 155-238 of these proteins are identical 
except for 2 amino acid changes - residues 145 and 146 are TA and AC for Venus and 
eCPF respectively, and the recombined fluorophores exhibit similar spectral properties 
(12,13).  
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Figure A.3. BiFC constructs to address HO-2 and BVR fluorescence reassembly. 
(A) BiFC fusion proteins to address the ability of soluble HO-2(1-288) and BVR to 
produce fluorescence. (B) BiFC fusion constructs to address the ability of full length 
HO-2 (residues 1-316) to produce fluorescence. The hatched rectangle represents the 
HO-2 transmembrane region. 
 
A.4.3 The requirement for the HO-2 membrane spanning region in HO-2/BVR 
BiFC   
 To test the ability of HO-2 and BVR to form a complex in mammalian cells and to 
test if the HO-2 membrane spanning region is required, full length and soluble HO-2 
(HO-2(FL) and HO-2(tn)) were cotransfected into HEK293 cells with their cognate BVR 
BiFC construct (Figure A.4). Both soluble and membrane bound HO produce a 
fluorescent BiFC complex when coexpressed with the cognate BVR BiFC construct, 
however the localization of the BiFC complexes are distinct. The BiFC pair with full 
length HO-2 exhibits perinuclear localization, similar to what is observed for staining of 
the ER (Figure A.4A). The BiFC complex for soluble HO-2 and BVR is diffuse 
throughout the entire cell (Figure A.4B). The localization of the BiFC complexes is 
HA BVR N eCFP 155-238 C 
FLAG HO-2 Venus 1-173 N C 
HO-2 C Venus155-238 HAN 
BVR C Venus1-173FLAGN 
A
B
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consistent with the expected localization of the HO-2 forms. Full length HO-2(FL) is 
expected to be membrane bound at the ER while soluble HO-2(tn) is expected to exhibit 
cytosolic localization. This result shows that the membrane spanning region of HO-2 
determines the subcellular localization of the HO-2/BVR BiFC complex, however the 
membrane spanning region of HO-2 is not required for the formation of an HO-2/BVR 
BiFC complex as BiFC fluorescence is apparent under both conditions. 
 
 
 
Figure A.4. Subcellular localization of HO-2 and BVR BiFC complex is dependent 
on the HO-2 membrane spanning region. Cells co-expressing HO-2(1-316).VN173 
and BVR.Cc155 (A) or cells co-expressing HO-2(1-288).VC155 and BVR.VN173 (B) 
were stained with Hoechst (blue) and ER tracker (red).  BiFC is shown in green. 
 
 To characterize the subcellular localization of the HO-2(FL)/BVR BiFC complex 
in greater detail, the colocalization of HO-2(FL)/BVR BiFC with various cell markers was 
determined (Figure A.5). The HO-2(Fl)/BVR BiFC pair was transfected into HEK293 
cells as described in the Methods section. Live cells were then stained with ER Tracker 
A
B
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(Biorad) and Hoechst nuclear stain. The fluorescence of live cells were imaged by 
collecting a series of z-stacks which were subjected to deconvolution using Imaris 
(Bitplane; South Windsor CT).  
 Figure A.5A shows representative images of two cells with a clear overlay of 
BiFC (green) and ER tracker (red) as yellow in the merged panel. To quantify the 
colocalizaton of the BiFC signal and ER, the Pearson’s coefficient was determined 
using the ImageJ colocalization tool JACoP (14). Complete positive colocalization 
results in a Pearson’s coefficient of 1, and no correlation results in a Pearson’s 
coefficient of 0. The BiFC signal has a strong positive correlation with the ER stain 
(Pearson’s coefficient = 0.966) supporting that the HO-2/BVR BiFC complex is located 
at the ER. As a positive control, the Pierce coefficient of BiFC with BiFC signal was 
determined (Pearson’s coefficient = 1.0). These results support that the HO-2(FL)/BVR 
BiFC complex localizes to the ER, the expected localization for full length HO-2. 
Furthermore, because BVR is cytosolic, these results support that HO-2(FL) is oriented 
properly with the catalytic domain towards the cytosol where it is available for binding 
with BVR. 
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Figure A.5. HO-2(1-316) and BVR BiFC colocalizes with the ER. (A) Cells co-
expressing  HO-2(1-316).VN173 and BVR.CC155 were stained with Hoechst (blue) and 
ER tracker (red).  BiFC is shown in green. The colocalization of BiFC (green) and ER 
tracker (red) is visible as yellow in the top left panel. Hoechst nuclear stain is blue. (B) 
Pearson’s coefficient was determined for the colocalization of BiFC and ER (top panel), 
BiFC and BiFC (lower panel) using ImageJ JACoP (14). 
 
 Flow cytometry was conducted to quantify the differences in BiFC signal for HO-
2(FL)/BVR and HO-2(tn)/BVR. Consistent with what is observed by microscopy, HO-
2(FL)/BVR produces less BiFC signal (~70%) compared with the HO-2(tn)/BVR BiFC 
pair (Figure A.6A).  
 While differences in BiFC signal between HO-2(FL)/BVR and HO-2(tn)/BVR 
could be interpreted as BVR binding less efficiently to HO-2(FL), differences in protein 
expression levels could also produce similar results. To determine the expression levels 
of the various BiFC constructs, equivalent total protein from cells lysates that were co-
transfected with the BiFC pairs was resolved by SDS-PAGE and subjected to Western 
blot analysis using antibodies specific for HO-2 or BVR. The relative expression of the 
HO-2 and BVR protein constructs was then determined by densitometry (ImageJ). HO-2 
and BVR proteins are both expressed at lower levels in the HO-2(FL)/BVR expressing 
cells relative to cells expressing the HO-2(tn)/BVR constructs (53% and 83% expression 
for HO-2(FL) and BVR respectively) (Figure A.6B). Thus differences in expression 
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levels for the BiFC fusion proteins are the likely cause for the differences in the BiFC 
signal intensity between HO-2(tn)/BVR and HO-2(FL)/BVR expressing cells. These data 
demonstrate, however, that both soluble and full-length HO-2 produce robust BiFC 
signal with their cognate BVR BiFC partners and that the HO-2 transmembrane region 
is not required for the formation of HO-2/BVR BiFC complexes, and thereby establishes 
a context in which the requirements of HO-2/BVR binding can be addressed 
quantitatively. 
 
 
Figure A.6. Membrane localization requirements for HO-2/BVR BiFC. (A) HEK293 
cells were transfected with the indicated BiFC constructs as described in the methods 
and YFP signal quantified by flow cytometry. (B) The relative expression of HO-2 or 
BVR constructs as determined by Western blot analysis of cellular lysates from HEK293 
cells. The bottom panels show the Western blot band that was quantified for 
densitometry, as described in the Methods section. 
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A.4.4 An analysis of BVR C-terminal cysteines in binding HO-2 
 In vitro chemical cross-linking studies between soluble HO-2(tn) and BVR are 
described in Chapter 2 (Spencer et al., manuscript in press). To briefly summarize, a 
complex between HO-2(tn) and BVR is stabilized by the heterobifunctional cross-linker 
LC-SPDP. These results are recapitulated from Figure 2.16 in this appendix as Figure 
A.7A. Because a complex between soluble HO-1(tn) (residues 1-265) and BVR is 
reported in the literature (2-5), cross-linking between HO-1(tn) and BVR was included 
as a positive control. In the HO-2 only sample, an HO-2 homodimer is also stabilized by 
the cross-linking reaction. Because HO-2(tn) and BVR are similar in size, a co-
purification of BVR with HO-2(tn) was conducted to determine if BVR was directly linked 
to HO-2(tn) in the cross-linked product (Figure A.7B). Indeed, BVR copurifies with HO-
2(tn) but not affinity resin alone, demonstrating that HO-2 and BVR are directly linked. 
The chemical cross-linker failed to stabilize a complex for an unrelated cysteine 
containing protein, RNase, and either HO-1(tn) or HO-2(tn) (Figure A.7C).  
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Figure A.7. Chemical cross-linking stabilizes an HO/BVR complex. (A) The 
heterobifunctional cross linker LC-SPDP stabilizes a complex between HO-1 or HO-2 
and BVR. (B) Reducing SDS-PAGE and Western blot of HO-2 pull down and 
associated BVR.  Lane 1: cross linking reaction, Lane 2: HO-2 only, Lane 3: BVR only. 
(C) No complex is trapped for HO-1 or HO-2 with RNAse. Crosslinking reactions 
contained 10 µM of the indicated protein. 
 
 Human BVR contains 5 cysteines that could be available for cross-linking with 
HO-2; C74, C204, C281, C292 and C293. Analysis of the HO-2(tn)/BVR complex by 
tryptic digest and LC-MS/MS identified C292 or C293 of BVR as being cross-linked to 
K264 of HO-2. The analysis was unable to distinguish between C292 and C293 as they 
occurred on the same peptide. 
 To determine if either C292 or C293 are required for BVR binding HO-2, C292 or 
C293 was substituted with a serine residue in the BVR BiFC expression construct. The 
HO-2(FL)/BVR, HO-2(FL)/BVR(C292S) and HO-2(FL)/BVR(C293S) BiFC pairs were 
cotransfected into HEK293 cells and BiFC signal quantified by flow cytometry (Figure 
A.8). A serine substitution at C292 or C293 has no effect on HO-2(FL)/BVR BiFC signal, 
A
B
C
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suggesting that neither of these residues are required for HO-2(FL)/BVR BiFC complex 
formation. 
 
 
 
Figure A.8. BVR cysteine requirements for HO-2/BVR BiFC. HEK293 cells were 
transformed with HO-2(FL) and the indicated BVR construct and BiFC signal quantified 
by flow cytometry. 
 
A.5 Discussion 
 In the current study we demonstrate that coexpression of HO-2 and BVR protein 
constructs that are fused with complementary halves of a split fluorophore results in 
fluorescence reassembly in both E. coli and mammalian cells. Co-expression of HO-
2/BVR GFPR constructs results in robust fluorescence in E. coli. Furthermore, the 
expression of the HO-2/BVR GFPR complex displays a diffuse pattern throughout the 
cell (Figure A.2A) . In E. coli, the expression of some exogenous proteins can result in 
the aggregation of proteins in inclusion bodies that could drive the reassembly of the 
GFP fragments independent of HO-2 and BVR. Fluorescent proteins that are 
aggregated in inclusion bodies, however, typically display a highly localized and 
punctate distribution in the bacterium (20,21). The diffuse distribution of the HO-2/BVR 
GFPR signal suggests that reassembly is not driven by the aggregation of HO-2 and 
BVR in inclusion bodies (Figure A.2A).  
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 The subcellular localization of the HO-2/BVR BiFC signal in mammalian cells is 
consistent with the expected diffuse (likely cytosolic) subcellular localization of HO-2(tn), 
which lacks the membrane spanning region, and  localization of membrane-bound HO-
2(FL) at the ER. BVR is predominantly present in the cytosol (22). These data 
demonstrate that the subcellular localization of HO-2 drives the localization of the BiFC 
complex. 
 These results demonstrate that BVR is capable of binding both soluble and 
membrane bound HO-2 in the mammalian cell and lacks a strict requirement for the 
HO-2 membrane spanning region or for the C-terminal cysteines of BVR for formation of 
the HO-2/BVR BiFC complex (Figure A.6 and Figure A.8). 
 Considering the high homology of HO-1 and HO-2 (55% identity and 76% 
similarity), the ability of HO-2 and BVR to form GFPR and BiFC complexes is consistent 
with reports that BVR binds HO-1 and may reflect a physiologically relevant event (2-4). 
However, split fluorophores can posses the ability to reassemble independent of the 
fusion binding partners (e.g. HO-2 and BVR) (11). To determine the degree of specificity 
for the BiFC reassembly, a binding interface for HO-2 and BVR must be identified. 
Disruption of the HO-2/BVR interface (e.g. mutagenesis), and subsequent loss of BiFC 
signal would support that the BiFC fluorescence observed in the current study is driven 
by HO-2/BVR binding rather than fluorophore reassembly. While various requirements 
for HO-2/BVR BiFC complex formation were tested (the HO-2 membrane spanning 
region, BVR C-terminal cysteines), these conditions did not markedly affect BiFC signal 
and are not required for the fluorescence observed. Additional mutations, such as 
truncation of the BVR C-terminus, could provide insight into the specificity of the HO-
2/BVR BiFC complex; whether it reflects a physiologic complex between HO-2 and 
BVR, and if so, what the interface of that complex might be. 
 In vitro studies to identify the HO-2/BVR interface, described in Chapter 2 of this 
thesis (Spencer et al, in press) have been conducted with the hopes that the results 
might clarify a mutagenesis scheme to test the specificity of the HO-2/BVR BiFC 
complex. However, NMR binding studies suggest that BVR binds HO-2 with 
considerably weaker affinity than what was expected according to published results, 
and fail to identify an interface for the two enzymes. In fact, in the absence of an 
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irreversible step such as chemical cross-linking or fluorescent reassembly, we are 
unable to detect an HO-2/BVR complex. In light of these results, while the cellular 
context of HO-2 and BVR may promote complex formation, it is also possible that the 
fluorescent reassembly methods are trapping an extremely weak or transient event that 
may or may not have physiologic relevance. 
A.6 Future directions 
 While at this time the existence and nature if the HO-2/BVR complex is 
unresolved, this work demonstrates HO-2 BiFC fusion proteins are capable of forming 
BiFC complexes with other BiFC fusion proteins (BVR) and this system could be used 
to address HO-2 protein interactions with additional proteins of the HO pathway, such 
as CPR. Both soluble and full-length HO-1 are reported to bind CPR, the electron 
transfer partner required for HO activity. Methods such as mutagenesis, lysine 
acetylation protection assays and crystallography have been used to define an interface 
for the HO-1/CPR complex (2-5,8,17,23). We have identified and characterized an HO-
2/CPR complex that is similar to what is described for HO-1 and CPR (see Chapter 2 of 
this thesis; Spencer et al, in press). Furthermore, the C-terminal membrane-spanning 
region of HO-1 (and HO-2) is thought to facilitate HO/CPR binding (7,8).  
 Also, in Chapter 2 of this thesis we use NMR and gel filtration methods to 
determine that soluble HO-2 exits as homodimer, however the physiologic relevance of 
the HO-2 homodimer is unknown. The crystal structure of the HO-2 homodimer has also 
been determined (24). The BiFC method could be used to determine if HO-2 forms a 
homodimer in cells and provide insight into the physiologic relevance of the HO-2 dimer. 
 The BiFC method represents a powerful tool that could provide information 
regarding the molecular and cellular requirements for HO-2 protein-protein interactions 
in the cell. Additionally, a tripartite complex between HO, CPR, and BVR has been 
proposed (25). A multicolor BiFC system has been used to study protein-protein 
interactions among multiple proteins, such as the transcription factors MIX, MAD and 
MAX, and could be used to interrogate interactions of HO-2, CPR and BVR in their 
native context of the cell (26). 
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